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“All scientific work is incomplete – whether it be observational or experimental. All 
scientific work is liable to be upset or modified by advancing knowledge. That does 
not confer upon us a freedom to ignore the knowledge we already have, or to 
postpone the action that it appears to demand at a given time.” 
Austin Bradford Hill, 1965.(1) 
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Abstract 
Introduction 
Observational studies have reported associations between levels of the amino acid 
homocysteine in the circulation and risk of cardiovascular disease. Oral 
administration of the synthetic B vitamins folic acid and cyanocobalamin (vitamin 
B12) can lower plasma total homocysteine levels. In the Western Norway B Vitamin 
Intervention Trial (WENBIT) and the Norwegian Vitamin Trial (NORVIT), patients 
with ischemic heart disease were randomized to groups receiving folic acid plus 
vitamin B12, or no such treatment, to assess whether they would benefit from 
lowered homocysteine levels with respect to major adverse clinical events, such as 
myocardial infarction, stroke, cardiovascular death or all-cause death. Using a 2 x 2 
factorial design, participants were also randomized to groups receiving vitamin B6 or 
no vitamin B6. 
Aims 
The overall aim of the present dissertation was to investigate the clinical effects of B 
vitamin treatment in patients with established ischemic heart disease. 
Materials and methods 
We used clinical and laboratory data on 6837 patients with ischemic heart disease, 
recruited from 36 hospitals in Norway (1998 to 2004) collected during in-trial follow-
up, and data on cancer incidence and cause-specific and all-cause mortality on these 
patients collected during extended follow-up throughout the year 2007. 
Clinical outcomes were analyzed for groups assigned to folic acid plus vitamin B12 
treatment vs no folic acid/vitamin B12, and for groups assigned to vitamin B6 
treatment vs no vitamin B6. Survival curves were constructed using the Kaplan-Meier 
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method, and estimates of hazard ratios with confidence intervals were obtained using 
Cox proportional hazards regression. 
Results 
Folic acid plus vitamin B12 treatment lowered plasma total homocysteine 
substantially in both trial populations. In the WENBIT study population, this 
treatment was not associated with the incidence of major adverse cardiovascular 
events or all-cause mortality during in-trial follow-up of median 38 months. In the 
combined NORVIT-WENBIT study population, it was not associated with the 
incidence of major adverse cardiovascular events or any of its constituents 
(myocardial infarction, stroke or cardiovascular death) during in-trial follow-up of 
median 39 months, or associated with long-term cardiovascular mortality during 
extended follow-up of median 78 months. However, among NORVIT-WENBIT 
participants with hyperhomocysteinemia at baseline, treatment with folic acid plus 
vitamin B12 was associated with increased risk of in-trial major cardiovascular 
events, and of long-term cardiovascular mortality. Exploratory analyses in NORVIT-
WENBIT showed that baseline plasma total homocysteine was not independently 
associated with cardiovascular outcomes, whereas homocysteine measured after 1-2 
months of folic acid plus vitamin B12 treatment was a strong predictor of in-trial 
major cardiovascular events. 
In the combined NORVIT-WENBIT study population, folic acid plus vitamin B12 
treatment was associated with increased cancer incidence, cancer mortality and all-
cause mortality during extended follow-up of median 78 months. These findings were 
consistent in both trial populations, among patients with age below or above the 
median, in both genders, among never and ever smokers and among patients with 
baseline serum folate level below or above the median. However, hazard ratios for 
folic acid plus vitamin B12 treatment vs no such treatment were higher among 
individuals with the TT genotype than among those with the CC or CT genotypes of 
the methylenetetrahydrofolate reductase 677CT polymorphism. 
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Vitamin B6 treatment led to a 10-fold increase in plasma levels of pyridoxal 5’ 
phosphate in both trial populations, but was not associated with outcomes during in-
trial follow-up in the WENBIT study population, or with any outcomes during in-trial 
or extended follow-up of the combined NORVIT-WENBIT study population. 
Discussion and conclusions 
Our findings with respect to cardiovascular outcomes are consistent with the null 
effects of homocysteine-lowering B vitamin treatment demonstrated in large 
randomized controlled trials to date. The increased risk of cardiovascular outcomes 
by folic acid plus vitamin B12 among patients with baseline hyperhomocysteinemia 
was contrary to what would be expected if homocysteine has a causal role in 
cardiovascular disease progression. Thus, B vitamins to lower homocysteine should 
not be recommended for patients with cardiovascular disease. 
The increased cancer incidence and cancer mortality during extended follow-up 
observed in the groups who received folic acid plus vitamin B12 for median 39 
months may be explained by the so-called acceleration phenomenon; that this 
treatment influenced growth in cancers that were silent at baseline or during trials, 
leading to excess subsequent clinical surfacing and diagnosis during extended follow-
up. However, reports on cancer outcomes from other completed homocysteine-
lowering B vitamin treatment trials to date do not support our findings, and our 
results need confirmation in other populations. 
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Definitions 
Cardiovascular disease Pathological conditions involving the 
cardiovascular system, including the heart, the 
blood vessels or the pericardium.(2) 
Clinical trial Any form of planned experiment which involves 
patients and is designed to elucidate the most 
appropriate treatment of future patients with a 
given medical condition.(3) 
Confounding The distortion of a measure of the effect of an 
exposure on an outcome due to the association of 
the exposure with other factors that influence the 
occurrence of the outcome. Confounding occurs 
when all or part of the apparent association 
between the exposure and outcome is in fact 
accounted for by other variables that affect the 
outcome and are not themselves affected by 
exposure.(4) 
Coronary artery disease Pathological processes of coronary arteries that 
may derive from a congenital abnormality, 
atherosclerotic, or non-atherosclerotic cause.(2) In 
the current dissertation, this term is used about the 
atherosclerotic disease. 
Effect modification Variation in the selected effect measure for the 
factor under study across levels of another factor 
(the modifier).(4) 
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Folate Naturally occurring B vitamin, including 5-
methyltetrahydrofolate prevailing in 
serum/plasma.(5) 
Folic acid Pteroylmonoglutamate, the synthetic fully oxidized 
form of folate used in fortified foods and vitamin 
supplements.(5) 
Fortification The deliberate addition of specific nutrient to foods 
as a means of providing the population with an 
increased level of intake. Generally synonymous 
with enrichment, supplementation, and restoration; 
in the USA enrichment is used to mean the addition 
to foods of nutrients that they do not normally 
contain, while fortification is the restoration of 
nutrients lost in processing.(6) 
Ischemic heart disease A disorder of cardiac function caused by 
insufficient blood flow to the muscle tissue of the 
heart. The decreased blood flow may be due to 
narrowing of the coronary arteries (coronary artery 
disease), to obstruction by a thrombus (coronary 
thrombosis), or less commonly, to diffuse 
narrowing of arterioles and other small vessels 
within the heart.(2) 
Risk (bio)marker A surrogate for an important biological process or 
(sub)clinical disease. The risk (bio)marker itself (as 
opposed to the process it represents) generally 
makes a poor target for therapy.(7) 
Risk factor An aspect of personal behavior or lifestyle, 
environmental exposure, or inborn or inherited 
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characteristic, which, on the basis of epidemiologic 
evidence, is known to be associated with a health-
related condition considered important to prevent. 
(2) 
Vitamins Organic substances that are required in small 
amounts for maintenance and growth, but which 
cannot be manufactured by the human body.(2) 
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1. Introduction 
1.1 Cardiovascular disease and cancer epidemiology 
Worldwide, cardiovascular disease (CVD) is the leading cause of death. In 2004, an 
estimated 17.1 million people died from CVD, representing 29% of all global deaths. 
Of these, an estimated 7.2 million died from coronary artery disease (CAD) and 5.7 
million from stroke.(8) Cancer is another leading cause of death, currently accounting 
for 13% of all global deaths, and being the second largest cause in most developed 
countries. In Norway, cardiovascular disease and cancer accounted for approximately 
35% and 25% of all deaths, respectively, in 2007.(9) 
1.2 Risk factors for coronary artery disease and cancer 
A risk factor is generally defined as “an aspect of personal behavior or lifestyle, 
environmental exposure, or inborn or inherited characteristic, which, on the basis of 
epidemiologic evidence, is known to be associated with a health-related condition 
considered important to prevent”.(2) When we refer to something as a “risk factor”, 
we are implying that it plays an etiologic or causal role in the development of 
disease.(7) Whereas modifiable risk factors are subject to intervention, non-
modifiable risk factors such as age, gender and other genetically determined 
characteristics are not. 
The Framingham risk score is based on data from a cohort of white people aged 30-
74 years, free of CAD, drawn from a free-living population of a suburb west of 
Boston, Massachusetts, US.(10) The risk factors are age, gender, total cholesterol, 
high-density lipoprotein (HDL) cholesterol, blood pressure, diabetes mellitus and 
current smoking. This score predicts a first coronary event (angina pectoris, coronary 
stenosis, myocardial infarction (MI), and coronary death), and has been found to be 
well calibrated for use in populations from the United States, Australia and New 
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Zealand.(11) The Systematic Coronary Risk Evaluation (SCORE) algorithm based on 
data from large European cohorts, was developed for clinical use to identify 
individuals in European populations at high risk of dying from CVD.(12,13) The 
SCORE variables include age, gender, total cholesterol, systolic blood pressure and 
current smoking. The SCORE has been found to overestimate the risk of fatal CVD 
in Norway. Therefore, a Norwegian score, NORRISK has been developed, based on 
more recent data from Norwegian cohorts and Statistics Norway.(14) NORRISK is 
currently recommended for individual risk assessment for primary prevention of 
CVD among Norwegians.(15) 
Once people have been diagnosed with CVD, the aim of secondary prevention is to 
control the widely accepted modifiable risk factors by life-style and medical 
interventions.(13,16) 
Common risk factors for cancer are smoking (active or passive), high alcohol 
consumption, overweight and obesity, physical inactivity, infection with certain 
micro-organisms, immunosuppressive treatment and family history of cancer.(17) It 
has been estimated that half of all cancer is preventable.(18) However, risk scores of 
cancer have not yet been developed. 
1.3 Biomarkers of cardiovascular risk 
A risk marker or biomarker of risk can be defined as a surrogate for an important 
biological process or subclinical disease. The risk (bio)marker itself (as opposed to 
the process it represents) generally makes a poor target for therapy. On the other 
hand, studying their potential role may improve knowledge of disease 
mechanisms.(7) 
Emerging markers of cardiovascular risk have been identified by advances in 
laboratory medicine and imaging, and quite a few are made widely available for 
clinicians over the past 10 to 15 years.(19) However, the clinical relevance of these 
markers has been limited, as judged by their ability to improve risk stratification 
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performed by conventional risk scores.(20) Also, there is the question of how 
investigations of possible risk biomarkers should be performed.(21-23) 
Among the most extensively examined biochemical markers for cardiovascular risk 
are high sensitive C-reactive protein (CRP), lipoprotein(a) and homocysteine.(19,24) 
1.4 Homocysteine 
Homocysteine is a sulfur-containing amino acid not found in foods that is produced 
from the metabolism of the essential amino acid methionine. It is a key intermediate 
in the process of generating methyl (CH3), or one-carbon, units for transmethylation 
reactions that are fundamental to all life forms. Adequate intake of methyl group 
sources (dietary choline, betaine, serine and methionine), and of coenzymes in one-
carbon metabolism (folate, vitamins B12 [cobalamin], B6 [pyridoxal 5’ phosphate, 
PLP] and B2 [riboflavin]), is necessary to ensure sufficient supply of methyl 
groups.(25) 
The homocysteine metabolism is illustrated in Figure 1 (to the right). Methionine is 
adenosylated to form S-adenosylmethionine (AdoMet), which is used as a universal 
methyl donor, yielding S-adenosylhomocysteine (AdoHcy) as a side product. 
AdoHcy then undergoes hydrolysis to form homocysteine and adenosine. In most 
cells, homocysteine can be remethylated to methionine via the transfer of a methyl 
group from 5-methyl-tetrahydrofolate (5-methyl-THF). In hepatic and renal cells, 
homocysteine can alternatively be remethylated by the transfer of a methyl group 
from betaine. Ultimately, homocysteine can be irreversibly combined with serine to 
form cystathionine, which is further converted to cysteine by transsulfuration 
reactions. Abnormalities in any of the steps in these metabolic pathways may result in 
pathologically elevated homocysteine levels.(25) 
Intracellular homocysteine concentration is kept low through remethylation, 
catabolism and export. In plasma a small (1%) amount of homocysteine is found in 
the reduced, non-protein-bound form, and the remainder in the oxidized forms, of 
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which 30% non-protein-bound, and 70% protein-bound. The sum of all homocysteine 
forms in plasma is denoted total homocysteine (tHcy).(26) The non-protein-bound 
homocysteine may be filtered by the renal glomeruli, but only a small fraction (1%) 
of the filtered load is subsequently excreted in the urine.(25) 
 
 
Figure 1. The homocysteine and folate metabolism 
10fTHF, 10-formyltetrahydrofolate; 5fTHF,5-formyltetrahydrofolate; AdoHcy, S-adenosylhomocysteine; AdoMet, 
S-adenosylmethionine; B12, vitamin B12 (cobalamin); B2, vitamin B2 (riboflavin); B6, vitamin B6 (pyridoxal 5’ 
phosphate); Bet, betaine; BT, betaine-homocysteine methyltransferase; CHTHF, methenyl tetrahydrofolate; CL, 
cystathionine gamma-lyase; CS, cystathionine beta-synthase; Cys, cysteine; Cysta, cystathionine; DHF, 
dihydrofolate; DMG, dimethylglycine; DR, dihydrofolate reductase; dTMP, deoxythymidine monophosphate; 
dUMP, deoxyuridine monophosphate; FA, folic acid; Gly, glycine; GT, glycine N-methyltransferase; Hcy, 
homocysteine; MA, methionine adenosyltransferase; Met, methionine; MR, 5,10-methylenetetrahydrofolate 
reductase (MTHFR); MS, methionine synthase; MT, methyltransferase; MTHF, 5,10-methylene-tetrahydrofolate 
(5,10-methylene-THF); mTHF, 5-methyltetrahydrofolate (5-methyl-THF); R, methyl acceptor; R-CH3, methylated 
molecule; Sar, sarcosine; Ser, serine; SH, S-adenosylhomocysteine hydrolase; ST, serine 
hydroxymethyltransferase; THF, tetrahydrofolate; TS, thymidylate synthase. 
Modified from (27). 
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1.5 Folate and folic acid 
Folate is the term used to describe a group of compounds derived from 
tetrahydrofolate (THF) which is a B vitamin mainly present in green leafy vegetables 
such as asparagus, spinach and broccoli, in legumes, whole grains and citrus 
fruits.(28,29) Naturally occurring folates predominantly exist as the reduced 
derivative 5-methyl-THF, which also is the main (>90%) circulating form of 
folate.(30) 
Folic acid (pteroylmonoglutamate) is the synthetic and fully oxidized form of folate 
used in fortified foods and vitamin supplements.(31) The bioavailability of folic acid 
is probably higher than that of natural occurring folates.(32-36) Folic acid is readily 
transported though the intestinal brush border, and is reduced to THF by 
dihydrofolate reductase in the liver, before it enters the one-carbon metabolism within 
the cells.(37) However, due to the limited capacity of dihydrofolate reductase,(37) it 
can also be found as unmetabolized folic acid in the circulation.(38-41) 
The folate metabolism is illustrated in Figure 1 (to the left). Intracellular folates 
function as a family of coenzymes that carry and activate methyl units, which are 
essential for DNA biosynthesis and methylation reactions. In DNA biosynthesis, the 
folate intermediate, 5,10-methylene-THF, serves as a methyl donor to convert 
deoxyuridine monophosphate into the DNA precursor deoxythymidine 
monophosphate. In methylation reactions, 5-methyl-THF acts as a substrate for the 
conversion of homocysteine into methionine catalyzed by methionine synthase (see 
above), and thus for the synthesis of the universal methyl group donor AdoMet.(42) 
1.6 Vitamins B12, B6 and B2 in the one-carbon 
metabolism 
Vitamin B12 is the coenzyme for methionine synthase in the remethylation of 
homocysteine to methionine. Vitamin B6 is the coenzyme for cystathionine beta-
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synthase and for cystathionine gamma-lyase in the transsulfuration of homocysteine, 
in addition to being involved in a wide range of other metabolic pathways.(43,44) 
Vitamin B2 is the coenzyme for methylenetetrahydrofolate reductase (MTHFR) 
catalyzing the conversion of 5,10-methylene-THF to 5-methyl-THF.(45) 
1.7 The methyltenetrahydrofolate reductase 677CT 
polymorphism 
Levels of B vitamins and homocysteine in the circulation are in part genetically 
determined. A common mutation in the gene encoding for MTHFR is the C to T 
substitution at nucleotide 677 (677CT), which results in the amino acid change 
from alanine to valine in the catalytic domain of the protein. This creates a thermo 
labile enzyme with reduced catalytic activity.(46) People with the TT genotype have 
lower levels of serum/plasma folate and higher levels of plasma tHcy, especially in 
conditions with low serum/plasma folate.(45,47,48) Thus, the presence or absence of 
the T allele can be considered a random allocation – so-called Mendelian 
randomization (49) – into groups with life-long differences in plasma tHcy levels. 
The prevalence of the TT genotype varies widely between regions and ethnic 
groups.(46) In Norway, the frequency of the T allele is approximately 28%, and the 
prevalence of TT homozygotes approximately 8% based on a large study of the 
general population.(50) 
1.8 Homocysteine and cardiovascular disease 
Homocysteine was first considered as pro-atherogenic (51) after the demonstration of 
vascular occlusive disease in autopsies of young adults with homocystinuria, an 
inborn error of metabolism in which cystathionine beta-synthase is deficient.(52) 
Observational studies during the nineteen eighties and nineties demonstrated that 
circulating tHcy is associated with CVD.(53) This research was facilitated by the 
development of analysis methods of tHcy in plasma.(54) In cohort studies from 
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Norway, tHcy was an independent predictor of MI in the general population,(55) and 
a strong predictor of all-cause mortality in patients with angiographically confirmed 
CAD.(56) 
In experimental settings, elevated levels of circulating homocysteine have been 
shown to induce endothelial dysfunction and injury, and activation of circulating 
platelets and leucocytes.(57) 
Also, two meta-analyses of studies of CVD incidence across the MTHFR 677 
genotypes up to 2001 supported that homocysteine may be causally related to 
CVD.(47,48) 
1.9 Homocysteine-lowering B vitamin trials 
Circulating B vitamin levels, particularly of folate and cobalamin, are inversely 
related to tHcy levels,(58,59) and tHcy can easily be lowered by oral administration 
of these B vitamins. Based on the findings of observational and experimental studies 
indicating that homocysteine may be causally related to CVD, there was a strong 
demand for clinical studies to assess the effect of such homocysteine-lowering 
treatment.(60-63) Folic acid typically lowers tHcy by 25%, and synthetic vitamin 
B12 (cyanocobalamin) additionally lowers tHcy by up to 7%.(53) These substances 
are affordable and were considered safe to be used in pharmacological doses to lower 
tHcy in clinical settings. Thus, during the late nineteen nineties a series of 
randomized controlled trials (RCTs) using folic acid alone or in combination with 
vitamin B12 were initiated in patients with cardiovascular and chronic kidney 
disease.(64) Table A1 in Appendix I shows characteristics of 11 large (each including 
more than 1000 participants) completed homocysteine-lowering RCTs. 
1.10 Folate, folic acid and cancer 
Most observational studies have reported inverse associations between folate intake 
or plasma/serum folate and risk of colorectal cancer.(65-68) This has led to the 
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hypothesis that folate prevents cancer. However, associations of folate intake or 
levels have been inconsistent or absent for prostate,(69) lung (70,71) and breast 
cancer.(72-75) The proposed mechanisms behind folate prevention of cancer are that 
adequate folate supply ensures sufficient nucleotide synthesis and thereby genome 
stability, and supports proper global DNA methylation.(76,77) 
On the other hand, once cellular transformation has occurred and a proliferating 
neoplasm is established, folate becomes essential for tumor growth. Premalignant and 
malignant cells often have a much faster rate of replication (and therefore DNA 
synthesis) than their normal counterparts, hence abundant folate is thought to 
accelerate their growth.(77) Based on the ground-breaking observation that 
administration of folic acid to children with acute leukemia led to a rapid worsening 
of the disease process, antifolate drugs such as aminopterin and methotrexate have 
been used in cancer treatment since the late nineteen forties.(78) In line with the 
observed “acceleration-phenomenon”,(79) findings from experimental,(80-83) 
epidemiological,(84) and clinical (85) studies have also led to the question whether 
folic acid administered through fortified foods and dietary vitamin supplements may 
enhance growth of established cancer.(76,86) 
1.11 Folic acid food fortification and supplementation 
In 1998, the US (87) and Canada (88) implemented mandatory folic acid fortification 
of flour and grain products to increase folate status in women of childbearing age in 
order to reduce the risk of neural-tube birth defects. There was also a hope that this 
public health intervention would reduce cardiovascular morbidity and mortality due 
to the homocysteine-lowering effect.(60,89) By 2009, 52 other countries worldwide 
have implemented mandatory folic acid fortification,(90,91) and the UK Food 
Standards Agency recently restated its position that adding folic acid to flour should 
be mandatory.(92) In addition, several countries currently permit voluntary folic acid 
fortification of foods such as breakfast cereals and fat spreads.(93,94) 
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In the North American population, fortification has resulted in a substantial increase 
in circulating folate (95-100) and unmetabolized folic acid (40) concentrations. 
Two recent studies reported that 34.5% of the adult US population take dietary 
supplements containing folic acid, and that 2.7% of all and 5% of those older than 50 
years consume more than the tolerable upper level of folic acid (1 mg per day) 
through mandatory fortified cereal grain products combined with ready-to-eat cereals 
and/or dietary supplements.(100,101) 
In Norway there was no folic acid fortification of foods until 2007. Since then, small 
amounts of folic acid (20 g per 100 kckal) may be added to foodstuffs after special 
permission from the Norwegian Food Safety Authority.(102) Presently, only a few 
products (cookies baked with fortified flour, energy bars and vitamin drinks) 
containing folic acid are marketed.(103) 
Norwegian health authorities advice women to consume 0.4 mg per day of 
supplemental folic acid in addition to dietary folate when planning to get pregnant, 
and during the first trimester of pregnancy.(104) In 2007, 26.2% of birth giving 
mothers reported having taken folic acid supplements prior to conception and 60.5% 
reported having taken such supplements during pregnancy.(105) However, there are 
no recent studies documenting the use of over-the-counter dietary supplements 
containing folic acid in the general Norwegian population. The relatively low serum 
folate levels found among participants of the Hordaland Homocysteine studies, a 
large cohort of the general adult population, indicate that the consumption was 
modest during the nineteen nineties.(106,107) Also, the content of folic acid in 
supplements in Norway is low; at most 0.2 mg per recommended daily dose.(108) 
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2. Aims of the present study 
The overall aim of the present dissertation was to investigate the clinical effects of B 
vitamin treatment in patients with established ischemic heart disease (IHD). 
The specific aims were to 
1. assess the effect of B vitamin treatment on cardiovascular morbidity and all-
cause mortality in the Western Norway B Vitamin Intervention Trial (Paper I) 
2. assess the effect of B vitamin treatment on cardiovascular morbidity and 
mortality in the populations of the Norwegian Vitamin Trial and the Western 
Norway B Vitamin Intervention Trial combined, and after extended follow-up 
(Paper II) 
3. assess the effect of B vitamin treatment on cancer outcomes and all-cause 
mortality in the populations of the Norwegian Vitamin Trial and the Western 
Norway B Vitamin Intervention Trial combined, and after extended follow-up 
(Paper III) 
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3. Materials and methods 
3.1 The Western Norway B Vitamin Intervention Trial 
Primary hypothesis 
Among patients with CAD or aortic valve stenosis, daily treatment with 
homocysteine-lowering B vitamins would reduce the risk of serious adverse 
cardiovascular events (cardiovascular mortality, MI, unstable angina and 
thromboembolic stroke) with at least 20% during a follow-up of mean 4 years.(109) 
Design 
Two-center, randomized, double-blind, placebo-controlled, clinical, secondary 
prevention study. 
Population 
Patients eligible for randomization were men and women aged 18 years or older 
undergoing coronary angiography for suspected CAD and/or aortic valve stenosis at 
Haukeland University Hospital or Stavanger University Hospital in Western Norway. 
Exclusion criteria were inability to follow-up, participation in other trials, known 
alcohol abuse, serious mental illness or active cancer. All participants provided 
written informed consent. The consent form is shown in Appendix II. 
From April 1999 to April 2004 a total of 3090 patients were included, of whom 2121 
(68.6%) were randomized at Haukeland University Hospital and 969 (31.4%) at 
Stavanger University Hospital. 
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Intervention and randomization 
Participants were randomly assigned, using a 2 x 2 factorial design, to 1 of 4 groups 
receiving a daily oral dose of 1 of the following treatments: (1) folic acid 
(pteroylmonoglutamate) 0.8 mg, plus vitamin B12 (cyanocobalamin), 0.4 mg, and 
vitamin B6 (pyridoxine), 40 mg; (2) folic acid, 0.8 mg, plus vitamin B12, 0.4 mg; (3) 
vitamin B6, 40 mg; or (4) placebo. The study medication (Alpharma Inc, 
Copenhagen, Denmark), was given in a single capsule. For the first 2 weeks after 
randomization, the groups allocated to folic acid plus vitamin B12 received an extra 
capsule with a loading dose of 5 mg of folic acid per day, while the other groups 
received an extra capsule of placebo. 
The randomization sequence was generated in blocks of 20 by Alpharma Inc, and 
study nurses assigned boxes of study capsules to participants in numerical order. The 
different capsules were indistinguishable by color, weight, or ability to dissolve in 
water. Participants, study and laboratory personnel, and the steering and end-point 
committees were unaware of the treatment allocation, and the randomization code 
was kept at Alpharma Inc until data entry was completed. 
Participants were given conventional post-angiography medical treatment, and 
underwent myocardial revascularization procedures and/or valve surgery at the 
discretion of the treating physician. They were requested to abstain from taking 
dietary supplements containing B vitamins. 
Data collection 
Demographic, clinical, and routine laboratory data were obtained by study personnel, 
and heart catheterization with coronary angiography was performed by cardiologists. 
Participants were scheduled for follow-up visits with interview, clinical examination 
and blood sampling at 1 month, 1 year and at a final study visit. If unable or 
unwilling to attend study visits, participants were interviewed by telephone or by 
letter. Also, participants provided information through self-administered 
questionnaires. Participants were asked about hospital admissions, and copies of 
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hospital records were retrieved by mail. The paper forms used in the data collection 
are shown in Appendix II. 
In addition, archives of the hospitals in the West of Norway were searched for 
information on all participants’ hospital admissions, and copies of records on possible 
events were collected. Data on deaths were obtained from the Cause of Death 
Registry and on incident cancer from the Cancer Registry in Norway, using the 
unique 11-digit person number for each participant. 
Data were entered into to the computerized study database by trained study 
personnel, and data checks performed before the database was locked prior to the 
disclosure of the randomization code. 
Clinical end points 
The primary clinical end point was a composite of all-cause death, non-fatal acute 
MI, acute hospitalization for unstable angina pectoris, and of non-fatal 
thromboembolic stroke (infarction). Secondary end points were fatal and non-fatal 
acute MI, acute hospitalization for angina pectoris, stable angina pectoris with 
angiographically verified progression, myocardial revascularization procedures, and 
fatal and non-fatal stroke. Incident cases of newly diagnosed cancer, except basal cell 
cancer, were recorded as a measure of safety. All clinical events were adjudicated by 
members of the end-points committee. 
Laboratory analyses 
Blood samples obtained at baseline and 3 times during follow-up, were collected and 
processed by study personnel. Routine blood analyses were performed by the hospital 
laboratories. Blood samples for assessment of B vitamins and tHcy were usually 
immediately stored at –80°C until analyzed at Bevital AS by microbiological 
(110,111) and chromatography-mass spectrometry (112,113) methods. 
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Organization and approvals 
See Appendix III. 
3.2 The Norwegian Vitamin Trial 
Primary hypothesis 
Among patients having undergone an acute MI 1-7 days before inclusion, daily 
treatment with homocysteine-lowering B vitamins would reduce the risk of serious 
adverse cardiovascular events (cardiovascular mortality, recurrent MI or stroke) with 
at least 20% during a follow-up of mean 3.5 years.(114) 
Design 
Multi-center, randomized, double-blind, placebo-controlled, clinical, secondary 
prevention study. 
Population 
Patients eligible for randomization were men and women aged 30 to 85 years who 
had been hospitalized for an acute MI within 7 days before inclusion in one out of 35 
hospitals in Norway. Exclusion criteria were the presence of coexisting disease 
associated with a life expectancy of less than 4 years, prescribed treatment with B 
vitamins or untreated vitamin B deficiency, or inability to follow the protocol, as 
judged by the investigator. All participants provided written informed consent. The 
consent form is shown in Appendix IV. 
From December 1998 to March 2002 a total of 3749 patients were recruited, of whom 
1902 (50.7%) were randomized from hospitals in the South-Eastern, 824 (22.0%) in 
the Western and Central, and 1023 (27.3%) in the Northern part of Norway. 
 31
Intervention and randomization 
The B vitamin intervention and the randomization procedure were identical as in 
WENBIT, see section 3.1. 
Participants were given standard post-MI medical treatment, and underwent 
myocardial revascularization procedures at the discretion of the treating physician. 
They were requested to abstain from taking supplements containing B vitamins. 
Data collection 
Demographic, clinical, and routine laboratory data were obtained by the investigators 
and study nurses at the 35 study centers. Participants were scheduled for follow-up 
visits with interview, clinical examination and blood sampling 1-2 months after 
randomization and at the end of the intervention. If unable or unwilling to attend 
study visits, participants were interviewed by telephone or by letter. Also, 
participants provided information through self-administered questionnaires. The 
paper forms used in the data collection are shown in Appendix IV. 
Data on possible events were collected at the hospitals by study nurses, who filled in 
forms and submitted relevant discharge letters and medical record notes. For deaths 
that occurred outside the hospital, a copy of the death certificate was retrieved from 
the Cause of Death Registry. If deemed necessary by the end-points committee, 
additional information on the death was requested from the physician in charge. 
Data were entered into to the computerized study database by trained study 
personnel, and data checks performed before the database was locked prior to the 
disclosure of the randomization code. Later, final data on incident cancer were 
obtained from the Cancer Registry in Norway, using the unique 11-digit person 
number for each participant. 
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Clinical end points 
The primary clinical end point was a composite of coronary death, non-fatal acute 
MI, and of fatal and non-fatal stroke. Secondary end points were acute MI, 
hospitalization due to unstable angina pectoris, myocardial revascularization 
procedures, stroke and all-cause death. Incident cases of newly diagnosed cancer, 
except basal cell cancer, were recorded as a measure of safety. All end points were 
adjudicated by members of the end-points committee. 
Laboratory analyses 
Blood samples obtained at baseline and 2 times during follow-up, were collected and 
processed by laboratory personnel at the study centers. Routine blood analyses were 
performed by the hospital laboratories. Blood samples for assessment of B vitamins 
and tHcy were sent within 48 hours by mail to the laboratory of Bevital AS and 
stored at –80°C before analyzed by microbiological (110,111) and chromatography-
mass spectrometry (112,113) methods. 
Organization and approvals 
See Appendix V. 
3.3 The NORVIT-WENBIT combined analyses and 
extended follow-up 
Background and objectives 
NORVIT and WENBIT were planned as two separate but very similar trials; with 
similar patients, identical study design, identical study treatment regimen and doses, 
with similar follow-up routines and blood sampling procedures, to use the same 
central laboratory for blood analyses, and to have similar clinical end points. The 
principal investigators cooperated from the start of the planning of the two trials, the 
steering committees of both trials had overlapping representation, and there was an 
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intention to combine the results from the two trials when the separate results had been 
published. Also, both trials planned to extend the follow-up of the participants after 
the end of the intervention for the investigation of possible long-term effects. 
The data collected during in-trial and post-trial follow-up on the close to seven 
thousand participants in NORVIT and WENBIT were combined to investigate 
a) effects of the B vitamin treatment on incidence of major adverse 
cardiovascular events (MACE) and of cardiovascular mortality during the trial 
period and during post-trial follow-up, and whether there were certain 
subgroups that may benefit or suffer harm from the intervention 
b) effects of the B vitamin treatment on risk of developing cancer, dying from 
cancer and all-cause mortality during the trial period and during post-trial 
follow-up 
Design 
Combined analyses of data from the two RCTs NORVIT and WENBIT, and from 
post-trial observational follow-up of the trial cohorts through December 31, 2007. 
Population 
A total of 6837 individuals who participated in NORVIT or WENBIT were included 
in the combined analyses. 
Post-trial observational follow-up 
NORVIT was terminated in March, 2004, and WENBIT in October, 2005. When the 
primary results were available, participants were informed by letter that there was no 
apparent health benefit from the B vitamin intervention, and that such vitamin 
supplementation was not recommended as secondary prevention for patients with 
IHD. These letters are shown in Appendix VI. The post-trial follow-up did not imply 
any further personal contact or patients contributions. 
 34
Data collection 
Data from NORVIT and WENBIT were standardized and merged into one file 
containing demographic, clinical and laboratory data. 
Data on incident cancer and on cause-specific mortality by December 31, 2007, were 
obtained by linkage of the unique personal identification numbers to the Cancer 
Registry of Norway and to the Cause of Death Registry at Statistics Norway in April 
2009, when complete data were available. 
Clinical end points 
The primary and secondary end points in the NORVIT-WENBIT combined analyses 
and extended follow-up are listed in Table 1 below. 
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Table 1. End points in the NORVIT-WENBIT combined analyses and extended follow-up 
Term  Definition 
Primary cardiovascular 
end point during in-trial 
follow-up 
 A composite of major adverse cardiovascular events defined as cardiovascular 
death, non-fatal acute MI, except procedure related MIs, and of non-fatal stroke. 
Secondary cardiovascular 
end points during in-trial 
follow-up 
 Fatal and non-fatal acute MI, including procedure related MIs. 
Fatal and non-fatal stroke. 
Acute hospitalization for angina pectoris. 
Myocardial revascularization procedures, except PCI and CABG performed within 
6 months after index MI in NORVIT, or procedures determined by baseline 
coronary angiography in WENBIT. 
Cardiovascular end point 
during extended follow-up 
 Cardiovascular death. 
Primary cancer end point 
during extended follow-up 
 Incident new cancer registered in the Cancer Registry of Norway, except non-
melanoma skin cancers. 
Cancer death. 
Secondary cancer end 
point during extended 
follow-up 
 Incident new cancer subtypes registered in the Cancer Registry of Norway, except 
non-melanoma skin cancers. 
Cancer subtype death. 
Cardiovascular death  Death with underlying cause of death coded as International Statistical 
Classification of Diseases, 10th Revision, codes I00 to I99, or code R96 by the 
Cause of Death Registry. 
Cancer death  Death with underlying cause of death coded as International Statistical 
Classification of Diseases, 10  Revisionth , codes C00 to C97by the Cause of Death 
Registry. 
Acute MI  NORVIT: As specified in (115), the online supplementary appendix. 
WENBIT: Following the definition of acute MI published by The Joint European 
Society of Cardiology/American College of Cardiology Committee in 2000.(116) 
Stroke  NORVIT: As specified in (115), the online supplementary appendix. 
WENBIT: Following the definition of stroke published by the American College of 
Cardiology Committee in 2001.(117) 
Cancer  Incident cancer registered in the Cancer Registry or Norway, excluding non-
melanoma skin cancers. 
CABG, coronary artery bypass graft surgery; MI, myocardial infarction; PCI, percutaneous coronary intervention. 
 
Further laboratory analyses 
Plasma cotinine, a biomarker for tobacco exposure,(118) was determined by tandem 
mass spectrometry.(119) Genotyping of the MTHFR gene (NCBI Entrez Gene 4524) 
677CT polymorphism, was performed using MALDI-TOF mass 
spectrometry.(120) 
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Organization and approvals 
The protocol for the NORVIT-WENBIT combined analyses and extended follow-up 
was approved by both steering committees and by the Regional Committee for 
Medical and Health Research Ethics, the Data Inspectorate, and the Norwegian 
Directorate of Health. The NORVIT-WENBIT study is authorized to obtain data 
from national health registries and hospitals extending to the end of 2014, and is 
registered with clinicaltrials.gov, Identifier: NCT00671346. 
3.4 Statistical methods 
Differences between groups were tested with Chi-squared test for categorical 
variables and parametric or non-parametric methods for continuous variables, as 
appropriate.(121) Pearson partial correlations were used to explore the relationship 
between baseline levels of plasma tHcy and serum or plasma B vitamins or serum 
creatinine, after logarithmical transformation of the skewed variables, and with 
adjustment for possible confounders (paper II).(121,122) 
The 2 x 2 factorial design allowed separate assessments of effects from the folic acid 
plus vitamin B12 and the vitamin B6 interventions.(3,123) The main analyses were 
comparison of treatment effect between participants allocated to folic acid plus 
vitamin B12 (folic acid groups) vs no such treatment (non-folic acid groups) and 
between participants allocated to vitamin B6 (vitamin B6 groups) vs no such 
treatment (non-vitamin B6 groups). Comparisons were made according to the 
intention to treat principle, as well as according to the per protocol principle.(3) 
We constructed survival curves using the Kaplan-Meier method, and analyzed the 
differences in survival between groups by the log-rank test. We estimated hazard 
ratios (HRs) and 95% confidence intervals (CIs) using Cox proportional hazard 
regression.(121) The Cox regression analyses were performed unstratified and 
unadjusted (paper I), or stratified for trial, unadjusted as well as adjusted for possible 
confounders (papers II and III). In the latter analyses, proportional hazards 
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assumptions were tested by Stata’s estat phtest procedure based on Schoenfeld 
residuals,(124) and evidence of non-proportionality was not found. 
Survival time was calculated for each participant from the date of randomization to 
the date of the first event included in any of the end points, or to the end of the 
intervention in NORVIT or WENBIT, or to December 31, 2007. For fatal events, the 
date of death was used to calculate survival times. Participants who declined post-
trial follow-up (papers II and III) were censored at the date of their final study visit. 
Participants who emigrated were censored at the date of last contact (in-trial) or the 
date of emigration in the National Registry. 
A two-sided statistical significance level of 0.05 was applied throughout, and the 
reported p values were not adjusted for multiple comparisons. We used the statistical 
software packages SPSS version 15.0 (SPSS Inc., Chicago, Illinois), S-PLUS, version 
7.0-8.0 (TIBCO Software Inc, Palo Alto, California) (paper I and III), Stata version 
10 (StataCorp LP, College Station, Texas) (paper II and III) and SAS version 9.2 
(SAS Institute, Cary, North Carolina) (Paper III). 
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4. Summary of results 
4.1 WENBIT population and primary outcomes (Paper I) 
Mean (SD) age of the participants was 61.6 (10.0) years, ranging from 28 to 87 years, 
and the majority (n = 2458, 79.5%) were men. The reason for referral to baseline 
angiography was stable angina pectoris (n = 2585, 83.7%), acute coronary syndromes 
(n = 461, 14.9%) and aortic valve stenosis (n = 44, 1.4%). Most participants had 2- or 
3-vessel disease (n = 1831, 59.3%). A total of 329 (10.8%) of participants reported 
regular use of over-the-counter supplements containing B vitamins prior to inclusion. 
The randomization procedure resulted in well-balanced intervention groups with no 
differences in baseline demographics or clinical characteristics. Table 2 shows 
baseline participant characteristics and treatment regimens following baseline 
angiography in WENBIT by gender. 
A total of 2532 (81.9% of all) took 50 to 100% of their study medication throughout 
follow-up. Mean (SD) plasma tHcy level was lowered by 30%, from 10.8 (4.5) 
μmol/L at baseline to 7.6 (2.2) μmol/L after 1 year of follow-up in the groups 
receiving folic acid plus vitamin B12 (p <0.001). Plasma tHcy remained unaltered in 
the groups receiving vitamin B6 alone or placebo. 
During a median 38 months of follow-up, 422 participants (13.7% of all) experienced 
an event in the composite primary end point of death, acute MI, unstable angina 
pectoris, or thromboembolic stroke. There were no statistically significant differences 
between the folic acid and non-folic acid groups, or between the vitamin B6 and non-
vitamin B6 groups in the survival analyses with respect to the primary end point. 
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Table 2. Baseline characteristics in men and women in WENBIT 
Characteristic  Men 
(n = 2458) 
 Women 
(n = 632) 
 P 
Value 
Age, mean (SD), y  61.0 (9.8)  64.0 (10.3)  <0.001 
Age >75 y, No. (%)  197 (8.0)  101 (16.0)  <0.001 
Body-mass index, mean (SD)a  27.0 (3.5)  26.7 (4.5)  0.18 
Systolic blood pressure, mean (SD), mm Hg  141 (20)  140 (21)  0.53 
Diastolic blood pressure, mean (SD), mm Hg  81 (11)  78 (11)  <0.001 
LVEF <50%, No. (%)  305 (12.4)  44 (7.0)  <0.001 
Hemoglobin, mean (SD), g/dL  14.6 (1.1)  13.4 (1.1)  <0.001 
Creatinine, mean (SD), μmol/L  94 (16)  81 (15)  <0.001 
eGFR <60 mL/min/1.73m2, No. (%)  198 (8.1)  162 (25.6)  <0.001 
Total cholesterol, mean (SD), mmol/L  5.0 (1.2)  5.3 (1.2)  <0.001 
HDL cholesterol, mean (SD), mmol/L  1.2 (0.3)  1.4 (0.4)  <0.001 
LDL cholesterol, mean (SD), mmol/L  3.1 (1.0)  3.2 (1.1)  0.002 
CRP, median (IQR), mg/L  1.9 (3.3)  2.1 (3.8)  0.02 
Cardiovascular history and risk factors, No. (%)         
MI  1064 (43.3)  216 (34.2)  <0.001 
PCI  528 (21.5)  109 (17.2)  0.02 
CABG  356 (14.5)  59 (9.3)  0.001 
Carotid-artery stenosis, TIA or stroke  150 (6.1)  42 (6.6)  0.61 
Other peripheral-artery disease  220 (9.0)  55 (8.7)  0.85 
Family history of premature CAD  765 (31.1)  262 (41.5)  <0.001 
History of hypercholesterolemiab  1403 (57.1)  434 (68.7)  <0.001 
Hypertensionc  1104 (44.9)  314 (49.7)  0.03 
Diabetes mellitusd  279 (11.4)  77 (12.2)  0.56 
Ex smokere  1287 (52.4)  193 (30.6)  <0.001 
Current smoker  703 (28.6)  172 (27.2)  0.11 
CAD at baseline angiography, No. (%)         
No- or non-significant coronary stenosisf  221 (9.0)  118 (18.7)  <0.001 
1-vessel disease  699 (28.4)  221 (35.0)  0.001 
2-vessel disease  664 (27.0)  162 (25.6)  0.48 
3-vessel disease  874 (35.6)  131 (20.7)  <0.001 
Medication following randomization, No. (%)         
Acetylsalicylic acid  2229 (90.7)  558 (88.3)  0.07 
Clopidogrel  622 (25.3)  150 (23.7)  0.42 
Warfarin  123 (5.0)  29 (4.6)  0.67 
Statins  2185 (88.9)  546 (86.4)  0.08 
Beta-blockers  1916 (77.9)  500 (79.1)  0.53 
ACE inhibitors/ARB  802 (32.6)  192 (30.4)  0.28 
Calcium channel blockers  537 (21.8)  156 (24.7)  0.13 
Loop-diuretics  221 (9.0)  87 (13.8)  <0.001 
Oral antidiabetics  156 (6.3)  43 (6.8)  0.68 
Insulin  82 (3.3)  24 (3.8)  0.57 
Procedures following randomization, No. (%)         
PCI  1103 (44.9)  256 (40.5)  0.05 
PCI with use of stent(s)  980 (39.9)  228 (36.1)  0.08 
CABG  629 (25.6)  107 (16.9)  <0.001 
Valve surgery  75 (3.1)  26 (4.1)  0.18 
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CABG, coronary artery bypass graft surgery; 
CAD, coronary artery disease; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; HDL, high-density 
lipoprotein; LDL, low-density lipoprotein; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous 
coronary intervention; TIA, transient ischemic attack. 
aBody-mass index was calculated as weight in kilograms divided by height in meters squared. bUntreated total cholesterol 
values of 6.5 mmol/L. cMedically treated or started treatment at trial entry. dIncluded diabetes mellitus type 1 or 2. eQuit 
smoking >1 month before trial entry. fNormal vessels or plaque(s) with <50% luminal diameter narrowing. 
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4.2 NORVIT-WENBIT population and laboratory findings 
(Papers II and III) 
A total of 6837 individuals were included in the combined analyses, of whom 6261 
(98.7%) of participants alive at end of in-trial follow-up were included in the post-
trial follow-up (Appendix Figure A1). Mean (SD) age was 62.3 (11.0) years, and 
76.5% of participants were men. Median (25-75 percentiles) baseline plasma tHcy 
was 11.1 (9.1-13.7) mol/L. Baseline plasma tHcy correlated with serum folate, 
serum creatinine and serum cobalamin (Table 3). 
 
Table 3. Pearson partial correlations between baseline total 
homocysteine, B vitamins and creatininea 
 tHcy Folate Cobalamin PLP Creatinine 
tHcy 1  
Folate 0.325b 1  
Cobalamin 0.197b 0.160b 1  
PLP 0.124b 0.386b 0.160b 1  
Creatinine 0.273b 0.029c 0.061b 0.024 1 
PLP, pyridoxal 5’ phosphate; tHcy, plasma total homocysteine. 
aAfter adjustment for age, gender, MTHFR 677CT polymorphism, hypertension, obesity (body-
mass index 30), diabetes mellitus, current smoking, prior myocardial infarction, prior 
percutaneous coronary intervention, prior coronary artery bypass graft surgery, prior carotid 
stenosis, transient ischemic attack or stroke, and indication for trial entry. bp <0.001. cp <0.05. 
 
A total of 1179 (17.3%) of participants had hyperhomocysteinemia (plasma tHcy 15 
mol/L), as currently defined.(26) Baseline clinical and laboratory characteristics, 
risk factor levels and concomitant medication in the combined NORVIT-WENBIT 
population according to the presence or absence of hyperhomocysteinemia are 
presented in Table 4. 
The frequency of the 677 T allele in the MTHFR gene was 28.9%, and 8.2% of 
individuals were homozygous for the TT genotype. Among individuals with the TT 
genotype, baseline median serum folate concentration was lower and plasma tHcy 
higher than among individuals with the CC or CT genotype (7.3 nmol/L vs 8.9 
nmol/L; p <0.001, and 13.1 mol/L vs 11.0 mol/L, p <0.001, respectively). 
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Table 4. Baseline characteristics and medication in NORVIT-WENBIT participants with 
or without hyperhomocysteinemia 
Characteristic tHcy 15 
(n = 1179) 
tHcy <15 
(n = 5635) 
P 
Value 
Included in NORVIT, No. (%) 883 (74.9) 2850 (50.6) <0.001
Included in WENBIT, No. (%) 296 (25.1) 2785 (49.4) <0.001
Age, mean (SD), y 67.4 (11.5) 61.3 ±10.5 <0.001
Male gender, No. (%) 915 (77.6) 4293 (76.2) 0.30
Body-mass index, mean (SD)a 26.1 (3.7) 26.7 ±3.8 0.99
Systolic blood pressure, mean (SD), mm Hg 132 (22) 132 ±22 0.70
Diastolic blood pressure, mean (SD), mm Hg 75 (14) 76 ±13 <0.001
Total cholesterol, mean (SD), mmol/L 5.6 (1.4) 5.4 ±1.2 0.001
Creatinine, median (25-75 percentiles), mol/L 97 (84-114) 87 (78-97) <0.001
tHcy, median (25-75 percentiles), mol/L 17.7 (16.1-20.6) 10.4 (8.8-12.1) <0.001
Folate, median (25-75 percentiles), mol/L 6.5 (4.9-8.9) 9.3 (6.9-13.5) <0.001
Cobalamin, median (25-75 percentiles), pmol/L 306 (239-391) 360 (280-452) <0.001
PLP, median (25-75 percentiles), nmol/L 27 (19-38) 34 (24-48) <0.001
MTHFR 677 genotype, No./Total No. (%)    
CC 487/1135 (42.9) 2806/5397 (52.0) <0.001
CT 460/1135 (40.5) 2244/5397 (41.6) 0.51
TT 188/1135 (16.6) 347/5397 (6.4) <0.001
Vitamin supplements, No. (%)b 265 (22.5) 1310 (23.2) 0.57
Risk factors, No./Total No. (%)    
Hypertension 495/1167 (42.4) 1987/5606 (35.4) <0.001
Obesityc 176/1173 (15.0) 960/5631 (17.0) 0.09
Diabetes mellitusd 129/1171 (11.0) 590/5614 (10.5) 0.61
Smoking status and cotinine    
Never smoker, No./Total No. (%) 328/1174 (27.9) 1603/5626 (28.5) 0.70
Ex smoker, No./Total No. (%)e 328/1174 (27.9) 1875/5626 (33.3) <0.001
Current smoker, No./Total No. (%) 518/1174 (44.1) 2148/5626 (38.2) <0.001
History of CVD, No/Total No. (%)    
MI 373/1163 (32.1) 1527/5602 (27.3) 0.001
PCI 106/1178 (9.0) 708/5635 (12.6) 0.001
CABG 103/1179 (8.7) 489/5635 (8.7) 0.95
Carotid artery stenosis, TIA or stroke 98/1172 (8.4) 250/5610 (4.5) <0.001
History of cancer, No. (%)f 69 (5.9) 228 (4.0) 0.006
Indication for trial entry, No. (%)    
Acute MI 912 (77.4) 3142 (55.8) <0.001
Unstable angina 14 (1.2) 123 (2.2) 0.03
Stable angina 244 (20.7) 2335 (41.7) <0.001
Aortic-valve stenosis 9 (0.8) 35 (0.6) 0.58
Concomitant medication, No./Total No. (%)    
Acetylsalicylic acid 932/1094 (85.2) 4926/5462 (90.2) <0.001
Warfarin 139/1086 (12.8) 415/5455 (7.6) <0.001
Lipid-lowering drugs 819/1091 (75.1) 4725/5453 (85.2) <0.001
Beta-blockers 940/1094 (85.9) 4634/5461 (84.9) 0.37
Calcium antagonists 180/1086 (16.6) 812/5447 (14.9) 0.16
ACE inhibitors/ARBs 469/1089 (43.1) 1746/5447 (32.1) <0.001
Diuretics 330/1088 (30.3) 787/5450 (14.4) <0.001
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CABG, coronary artery bypass graft surgery; MI, 
myocardial infarction; MTHFR, methylenetetrahydrofolate reductase; PCI, percutaneous coronary intervention; PLP, pyridoxal 5’ 
phosphate; TIA, transient ischemic attack. 
aBody-mass index was calculated as weight in kilograms divided by height in meters squared. bDaily or often use of vitamin 
supplements at trial entry. cBody-mass index 30. dIncluded diabetes mellitus type 1 or 2. eQuit smoking >1 month before trial 
entry. fIncluded any cancer except non-melanoma skin cancer. 
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Close to 85% of participants took 80% of the study-capsules throughout in-trial 
follow-up. In the folic acid groups, serum folate increased from a median 8.8 to 62.2 
mmol/L, p <0.001, and serum cobalamin from a median 352 to 508 pmol/L, p <0.001 
during the first 1-2 months of follow-up (Figure 2, Panels A and B). Treatment with 
folic acid plus vitamin B12 lowered plasma tHcy from a median 11.1 to 8.3 mol/L 
(25%) after 1-2 months of follow-up, p <0.001 (Figure 2, Panel C). Among patients 
with baseline hyperhomocysteinemia, plasma tHcy was lowered from a median 17.7 
to 11.2 mol/L (37%), p <0.001, whereas among patients with no 
hyperhomocysteinemia, plasma tHcy was lowered from a median 10.4 to 8.0 mol/L 
(23%), p <0.001. In the vitamin B6 groups, plasma PLP increased from a median 
33.3 to 357.0 nmol/L, p <0.001 (Figure 2, Panel D). 
 
 
Figure 2. Circulating levels of B vitamins and total homocysteine during trials. 
Median concentration of B vitamins and total homocysteine in serum or plasma. Error bars represent 25-75 
percentiles. 
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4.3 NORVIT-WENBIT cardiovascular outcomes (Paper II) 
During a median 39 months of in-trial follow-up, 531 (15.6%) of participants who 
received folic acid plus vitamin B12 vs 503 (14.7%) of those who did not receive 
such treatment experienced a MACE (HR, 1.07; 95% CI, 0.95-1.21; p = 0.28). In the 
vitamin B6 groups, a total of 524 (15.4%) of participants experienced a MACE vs 
510 (14.9%) of participants in the non-vitamin B6 groups (HR, 1.04; 95% CI, 0.92-
1.18; p = 0.53). During a median 78 months of extended follow-up, 317 (9.3%) of 
participants in the folic acid groups vs 287 (8.4%) of participants in the non-folic acid 
groups died from CVD (HR, 1.12; 95% CI, 0.95-1.31; p = 0.18). Long-term 
cardiovascular mortality was also similar in vitamin B6 groups and non-vitamin B6 
groups with 308 (9.0%) vs 296 (8.6%) cardiovascular deaths (HR, 1.06; 95% CI, 
0.90-1.24; p = 0.51). 
There was no evidence of effect modification of folic acid plus vitamin B12 
treatment, or of vitamin B6 treatment, by trial, age below or above the median (62.5 
years), gender or current smoking. However, in patients with hyperhomocysteinemia, 
treatment with folic acid plus vitamin B12 was associated with increased risk of in-
trial MACE (HR, 1.41; 95% CI, 1.12-1.77), and of long-term cardiovascular 
mortality (HR, 1.44; 95% CI, 1.11-1.86), p for interaction = 0.01 and 0.03, 
respectively. We could not demonstrate any effect modification by the MTHFR 677 
genotype. 
Figure 3 shows the results from the exploratory analyses of associations between 
plasma tHcy concentrations measured at baseline or at the follow-up visit 1-2 months 
later, and risk of in-trial MACE and long-term cardiovascular death, among 
participants assigned to folic acid plus vitamin B12 treatment. Baseline plasma tHcy 
was a significant predictor of in-trial MACE and long-term cardiovascular death in 
univariate analyses, but after adjustment for important confounders (age, gender, 
serum creatinine, hypertension, obesity, diabetes mellitus, current smoking, prior MI, 
prior PCI, prior CABG, prior carotid stenosis, transient ischemic attack or stroke, and 
indication for trial entry), baseline plasma tHcy was not associated with outcomes. 
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Notably, plasma tHcy measured at the follow-up visit after 1-2 months of folic acid 
plus vitamin B12 treatment, was significantly associated with increased risk of in-trial 
MACE (HR for every 5-μmol/L increment, 1.31; 95% CI, 1.09-1.56; p = 0.004), but 
not with long-term cardiovascular death (HR, 1.20; 95% CI, 0.96-1.50; p = 0.11), 
after adjustment for the aforementioned confounders (Figure 3). 
 
 
 
 
4.4  NORVIT-WENBIT cancer outcomes (Paper III) 
A total of 629 participants (9.2%) were diagnosed with new cancers during (n = 292) 
or after (n = 337) the trials. Diagnoses were based on histological, cytological, or 
other diagnostic examinations in 90.5%, 4.9%, and 4.1% of the incident cases, 
respectively. Three cases of cancer were based on information from death certificates 
only. A total of 496 participants (7.3%) died during the trials and 525 (8.4%) died 
during post-trial follow-up. Of the total 1021 deaths through December 31, 2007, 236 
(23.1%) were classified as cancer deaths. 
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Figure 3. Plasma total homocysteine as predictor of  outcomes in folic acid groups 
CI, confidence interval; CV death, cardiovascular death; MACE, major adverse cardiovascular events. 
Hazard ratios are shown for every 5-µmol/L incremen t in plasma tHcy. Squares are proportional to the 
number of participants included in the analysis. Analyses were restricted to participants in the folic acid 
groups with plasma tHcy measurements at baseline an d at the first follow-up visit which occurred 1-2 months 
after randomization (n = 3100). For the hazard ratios of MACE, participants who experienced a MACE 
between the two measurements were excluded from the  analysis (n = 109). A total of 77 and 89 participants 
had missing values for one or several of the confounding covariates used in the adjusted analyses for MACE 
and CV death, respectively. 
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After a median 39 months of treatment and an additional 38 months of post-trial 
observational follow-up, 341 participants (10.0%) who received folic acid plus 
vitamin B12 vs 288 participants (8.4%) who did not receive such treatment were 
diagnosed with cancer (HR, 1.21; 95% CI, 1.03-1.41; p = 0.02). A total of 136 (4.0%) 
who received folic acid plus vitamin B12 vs 100 (2.9%) who did not receive such 
treatment died from cancer (HR, 1.38; 95% CI, 1.07-1.79; p = 0.01). A total of 548 
patients (16.1%) who received folic acid plus vitamin B12 vs 473 (13.8%) who did 
not receive such treatment died from any cause (HR, 1.18; 95% CI, 1.04-1.33; p = 
0.01). Results were mainly driven by increased lung cancer incidence in participants 
who received folic acid plus vitamin B12. Vitamin B6 treatment was not associated 
with any significant effects. Figure 4 shows the Kaplan-Meier curves for cancer 
incidence, cancer mortality and all-cause mortality, and Figure 5 shows forest plots 
for cancer incidence according to cancer subtypes, for cancer mortality and all-cause 
mortality across folic acid plus vitamin B12 treatment.
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Figure 4. Kaplan-Meier curves for cancer incidence, cancer mortality and all-cause 
mortality during extended follow-up for folic acid groups vs non-folic acid groups. 
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Figure 5. Hazard ratios for cancer incidence according to cancer subtypes, cancer 
mortality and all-cause mortality across folic acid plus vitamin B12 treatment 
through extended follow-up. 
CI, confidence interval. Squares with horizontal lines indicate hazard ratios and the corresponding 99% 
confidence intervals. Diamonds indicate hazard ratios for total cancer incidence, cancer mortality, non-cancer 
mortality and all-cause mortality with 95% confidence intervals. *99% confidence intervals. **95% confidence 
intervals. 
 
Results were consistent in both trial populations, among patients aged younger than 
or older than the median age, in both genders, among never and ever smokers, and 
among patients with baseline serum folate levels of less than or more than the median 
(8.8 mmol/L), (all p for interaction 0.06). HRs for folic acid vs non-folic acid groups 
were higher among individuals with TT genotype than among those with CC or CT 
genotypes of the MTHFR 677CT polymorphism. For cancer mortality, we 
observed a statistically significant interaction (p = 0.03) between TT vs CC or CT 
genotypes and folic acid plus vitamin B12. 
Table 5 shows the estimated HRs for the primary end points across strata defined by 
serum folate and serum cobalamin levels measured during study treatment. 
Participants in the second serum folate quartile (range 8.6-23.9 mmol/L) or in the 
second cobalamin quartile (range 338-440 pmol/L) had the lowest cancer incidence, 
cancer mortality and all-cause mortality through extended follow-up, thus quartile 2 
was used as the reference category. HRs were statistically significantly higher for 
subjects in the fourth serum folate quartile (>62.7 mmol/L) as compared to those in 
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the second folate quartile. There were no such differences across quartiles of serum 
cobalamin. 
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5. Discussion and conclusions 
5.1 Strengths and limitations 
The strengths of WENBIT, and of the combined NORVIT-WENBIT study with 
extended follow-up, are first, the double-blinded randomized study design. A unique 
and important advantage of sufficiently large RCTs is that confounding variables, 
both known and unknown, will on average be distributed equally between 
intervention groups, and will therefore not bias the study results.(125) Furthermore, 
the analyses are based on a large number of well-described participants who adhered 
to the study medication, and biochemical treatment effects were corroborated through 
repeated measurements of circulating B vitamin and tHcy levels during the 
intervention. Third, the effect of the intervention was substantial with respect to 
serum folate and plasma tHcy, probably because of the relatively low serum folate 
levels at baseline. Finally, the study outcomes were either hard clinical end points 
occurring during trials with little loss to follow-up, adjudicated by professionals 
blinded for treatment allocation, or cancer and mortality end points throughout 
extended follow-up obtained from population based registries with almost 100% case 
coverage. 
For the investigation on cardiovascular end points, NORVIT and WENBIT were 
initially powered to detect a 20% decreased risk of major adverse cardiovascular 
events in the groups allocated to homocysteine-lowering treatment.(109,114) 
However, the event rates were lower than anticipated in both trials, probably due to 
improvements in standard secondary prevention among patients with IHD. The 
intervention was prolonged and the number of participants increased in NORVIT, 
which achieved a statistical power of 0.87 to detect the hypothesized difference in the 
primary end point.(115) Given the media reports on the preliminary results from 
NORVIT September 2005 (126) indicating a possible increased cancer risk by folic 
acid treatment, the intervention in WENBIT, however, was somewhat prematurely 
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terminated. In the end, WENBIT had a 67% power to detect the hypothesized 
difference. By combining data from the two trials and prolonging follow-up for 
cancer incidence and cause-specific mortality, the statistical power was increased, 
and we could perform subgroup analyses according to participant baseline 
characteristics. 
A limitation for the investigation of cancer outcomes was that the study design 
implied that all patients assigned to folic acid treatment also received vitamin B12. 
However, the observed associations between the primary end points and vitamin 
concentration measured during study treatment were confined to serum folate, 
suggesting that the adverse effects were mediated by folic acid. 
For the investigation of clinical end points in the NORVIT-WENBIT study (papers II 
and III), we encountered the problem of multiple comparisons. We performed 
survival analyses for several primary end points across folic acid plus vitamin B12 
treatment, and across vitamin B6 treatment, according to the 2 x 2 factorial design, 
which resulted in 4 comparisons in paper II and 6 comparisons in paper III. 
It is not always clear how adjustments should be done. An often used method is 
simply to multiply the obtained p value with the number of comparisons being 
made.(127) However, because the primary end points (in-trial MACE and long-term 
cardiovascular death in paper II, and cancer incidence, cancer mortality and all-cause 
mortality in paper III) were strongly associated with one another, we thought that 
adjusting for multiple testing for these end points may attenuate and conceal true 
effects.(128,129) 
In the subgroup analyses performed for the primary end points in paper II and III, 
resulting in a total of 24 and 18 comparisons, respectively, there was 70.8% and 
60.3% probability that one or more statistically significant interaction tests (p <0.05) 
could have appeared on the basis of chance alone. This was clearly stated in the 
methods sections. For the investigation on cancer subtypes, the end points were 
decided post hoc (after having received and analyzed the data). For these analyses, 
HRs with 99% CIs and no p values were presented, not to emphasize possible false 
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positive findings. We believe the above mentioned actions, including an emphasis on 
estimation rather than testing, should sufficiently alert the reader to the problem of 
multiple comparisons. 
5.2 The results in papers I and II in relation to other studies 
The null results of the homocysteine-lowering treatment on the primary end point in 
WENBIT are in line with results from two WENBIT substudies using intermediate 
end points. In a substudy among the 90 first participants randomized in WENBIT, 
none of the B vitamin interventions were associated with lowered inflammatory 
markers.(130) In another substudy among 348 WENBIT participants who underwent 
PCI at baseline, the homocysteine-lowering treatment was not associated with slower 
progression of the coronary atherosclerosis assessed by quantitative coronary 
angiography. A post hoc analysis of the latter study found that folic acid plus vitamin 
B12 treatment was associated with increased risk of rapid progression of the disease, 
expressed in percentage of diameter stenosis.(131) 
In the NORVIT-WENBIT study on cardiovascular outcomes, we confirmed the 
finding of an increased risk of MACE in participants with high baseline plasma tHcy 
levels, as was observed in the NORVIT primary results.(115) 
Our results are also fully in line with the results from other large homocysteine-
lowering B vitamin treatment trials with hard clinical end points published to 
date,(132-138) of which none have found overall beneficial effects (Table AI in 
Appendix I). The meta-analysis by the B-Vitamin Treatment Trialists’ collaboration 
using individual participant data from 8 (115,132-137,139,140) of these trials, has 
confirmed these findings.(141) 
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5.3 Why did homocysteine-lowering B vitamin treatment 
fail to prevent cardiovascular end points? 
There are at least three possible explanations to why the homocysteine-lowering B 
vitamin treatment did not prevent cardiovascular events in NORVIT or WENBIT, or 
in any other large similar RCTs. First, homocysteine may not have a causal role in 
atherosclerosis or thrombosis. Second, homocysteine-lowering treatment in 
individuals who have already been diagnosed with CVD may not have an effect. 
Third, the B vitamins to lower homocysteine may have adverse effects that offset the 
possible benefits of the homocysteine-lowering. 
The strongest evidence for a cause—effect relationship comes from consistent 
findings from different types of studies, preferably in diverse populations. After the 
initiation of NORVIT and WENBIT, there has been a rapid growth of prospective 
epidemiological evidence that circulating homocysteine is associated with the 
incidence (142) and prognosis (143-147) of CAD. A recent meta-analysis of cohort 
studies in healthy populations concluded that for each 5 mol/L increment in tHcy 
level, the risk of coronary events increases by 18%, independently of traditional CAD 
risk factors.(142) Also, a later large prospective study conducted in a Swedish 
population not exposed to folic acid fortification, and with similar circulating folate 
and tHcy levels as in the current study population, found that plasma tHcy measured 
at baseline was strongly and independently associated with risk of MI after 13 years 
of follow-up.(148) Thus, the epidemiological evidence pointing towards a causal 
relationship between homocysteine and CVD cannot be disregarded. However, the 
evidence up to 2001 from Mendelian randomization studies pointing towards 
homocysteine being causally related to CVD,(47,48) has been weakened by a later 
meta-analysis of studies up to 2004, which found no association of the MTHFR 
677CT polymorphism and CAD in European, North-American or Australian 
populations.(149) Furthermore, a recent large study among healthy US women found 
no association between TT genotype and CVD after 10 years of follow-up.(150) 
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Elevated plasma tHcy concentration could result from deficiencies of folate, vitamin 
B12 or vitamin B6, or impaired functions of enzymes involved in the B vitamin 
and/or homocysteine metabolism,(151) but it is also associated with a variety of 
factors not reflecting B vitamin status. The latter include several risk factors for CVD 
such as smoking, low physical activity, high blood pressure, and high total 
cholesterol, impaired renal function and cellular immune activation.(152-154) In the 
current study population, self-reported current smokers had both higher plasma tHcy 
and lower serum folate at baseline than ex-smokers and never smokers.(155) 
In the NORVIT-WENBIT folic acid groups, baseline tHcy was not an independent 
predictor, whereas the lowered tHcy after 1-2 months of folic acid and vitamin B12 
treatment was a significant predictor of subsequent MACE. This may imply that 
when the homocysteine remethylation pathway is saturated with 5-methyl-THF (from 
folic acid) and vitamin B12 (from cyanocobalamin), the remaining plasma tHcy level 
reflects disturbances in other metabolic pathways that are in turn causally linked with 
disease progression. This is also in line with our main finding that lowering plasma 
tHcy with folic acid plus vitamin B12 did not lower the risk of cardiovascular events. 
The increased risk of cardiovascular end points by folic acid plus vitamin B12 among 
NORVIT-WENBIT participants with baseline hyperhomocysteinemia could be a 
chance finding. Anyway, it was contrary to what would be expected if homocysteine 
has a causal role in CVD progression. Administration of pharmacological doses of 
these B vitamins could influence several biological systems, in addition to 
homocysteine remethylation.(151,156) One may therefore speculate that this 
intervention, which may promote DNA synthesis and cell proliferation, enhance 
neointimal proliferation in high-risk individuals with established 
atherosclerosis,(151,156) leading to an accelerated disease progression or vascular 
occlusion. 
Ultimately, to purely test whether homocysteine causes cardiovascular disease, it 
would be necessary to use an intervention modality that lowered homocysteine 
without affecting other biomarkers or risk factors.(157) 
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5.4 Why did vitamin B6 treatment fail to prevent 
cardiovascular end points? 
We found no separate effect of the vitamin B6 intervention on cardiovascular end 
points. This is in line with the results of recent observational studies demonstrating 
that low circulating levels of vitamin B6 may be a consequence of inflammation 
accompanying CAD and/or smoking, rather than being causally related to CAD.(158) 
Also two recent cross sectional studies in the general US (159) and older Puerto 
Rican US population,(160) observed inverse associations between CRP and PLP 
levels. Given the null results from the vitamin B6 intervention on levels of CRP and 
other inflammatory markers in the aforementioned WENBIT substudy,(130) the 
common cause for high levels of inflammation markers and low PLP levels in the 
circulation may be inflammation itself. 
5.5 The results in paper III in relation to other studies 
None of the other large homocysteine-lowering B vitamin trials that have reported 
cancer outcomes through in-trial follow-up found increased risk of cancer outcomes 
by the folic acid based homocysteine-lowering treatment.(134,137,161) In the 
aforementioned collaborative meta-analysis, the rate ratio for cancer incidence or 
cancer deaths during in-trial follow-up was 1.05 (95% CI, 0.97-1.10).(141) However, 
the adjudication method for cancer outcomes is not reported for all trials, and none of 
the trials in the collaboration (except for NORVIT and WENBIT) has prolonged the 
follow-up for cancer outcomes. Also, the baseline serum/plasma folate levels were 
higher in these trial populations than in the NORVIT and WENBIT populations, 
probably due to intake of folic acid fortified foods and/or a more common use of 
vitamin supplements than in the Norwegian trial populations. This may have 
obscured the effect of the additional folic acid through the intervention. 
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5.6 Why was folic acid treatment associated with cancer 
end points and all-cause mortality? 
Epidemiological evidence suggests that large relative increase of incident solid 
cancers in humans over a short period by chemical causes is implausible.(127,162) 
Thus, the exposure time of median 39 months in NORVIT-WENBIT is considered 
short. However it is likely that the administration of pharmacological doses of folic 
acid during this time may have led to accelerated growth in cancers that were initially 
silent, and that this resulted in the statistically significantly increased cancer 
incidence and mortality observed through extended follow-up.(163) 
Also, the finding of a dose/effect relationship across the second vs the fourth quartiles 
of on-treatment serum folate levels, and the increased risk of cancer mortality by folic 
acid treatment among participants with the TT genotype of the MTHFR 677CT 
polymorphism, is compatible with a real biological effect. 
The mechanisms may also include a direct effect of unmetabolized folic acid on 
cancer immune defense systems, although the in vitro findings of a folic acid 
associated disturbed function of natural killer cells published in 2006 (164) have not 
to our knowledge yet been confirmed by other research groups. 
5.7 Conclusions 
Despite the convincing epidemiological evidence that plasma tHcy predicts 
cardiovascular morbidity and mortality, the primary results from WENBIT and the 
combined results with extended follow-up of the NORVIT-WENBIT study 
population, add to the mounting proof that lowering homocysteine with folic acid 
based B vitamin treatment does not improve cardiovascular outcomes. This implies 
that homocysteine itself is probably not a causal factor in CVD, but rather a 
biomarker of increased risk. Routine measurement of tHcy in patients with CVD 
should not be performed unless there is clinical suspicion of folate (165) or vitamin 
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B12 deficiency,(166,167) or of cystathionine beta-synthase deficiency,(168) which 
should be treated with B vitamins. 
Our data indicate that folic acid may promote cancer growth, thus folic acid should 
not be prescribed to patients unless they have proven folate deficiency. Moreover, 
folic acid in pharmacological doses should not be added to over-the-counter vitamin 
supplements for others than women planning to get pregnant or in their first 3 months 
of pregnancy. 
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6. Further perspectives 
The hopes that a simple, affordable and presumably safe intervention with folic acid, 
vitamin B12 and/or vitamin B6 would reduce the risk of cardiovascular adverse 
events in patients with established cardiovascular or renal disease have been quashed 
by the null results from the portfolio of large B vitamin treatment trials with hard 
clinical end points published to date. Currently, only two such completed RCTs have 
not yet published their results; the VITAmins TO Prevent Stroke trial (169) and the 
SU.FOL.OM.3 trial.(170) In addition, a large primary prevention trial using enalapril 
with or without folic acid in patients with hypertension to evaluate the effects on 
incident strokes is under way, scheduled to be completed by March 2013.(171) 
Just recently, a meta-analysis of cohort studies on vitamin B6 intake and/or blood 
levels, concluded that blood PLP levels are inversely associated with risk of 
colorectal cancer, and stated that these findings “…need to be confirmed in large 
RCTs of vitamin B6 supplementation.”(172) However, the probability that new RCTs 
with adequate sample size (tens of thousands) and duration (decades) will be carried 
out to test the hypothesis that folic acid and other B vitamins prevent or promote 
CVD or cancer, is small, considering the high costs and low prospects of economic 
profits by such studies. 
To further evaluate possible disease modifying, clinical effects of B vitamin 
treatment, the strategy should rather be to explore short- and long-term effects of the 
interventions in RCTs already completed or under way. Meta-analyses with use of 
individual participants’ data will possibly provide some more answers,(64) especially 
if data from extended follow-up are obtained. A detailed analysis of cancer outcomes 
in 7 (115,133-137,139,140) of the RCTs in the B Vitamin Treatment Trialists’ 
collaboration,(64) also including individual participants’ data from 3 RCTs which 
used folic acid to prevent recurrent colorectal adenomas (85,173,174) is in 
progress.(109) Finally, when data from all 11 trials in the B Vitamin Treatment 
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Trialists’ Collaboration (115,132-137,139,140,169,170,175) are available, new meta-
analyses including data from more than 52000 participants should be performed. 
Also, there is much more basic laboratory research to be accomplished. It will be 
important to investigate interrelationships between the different B vitamins, their 
metabolites and related compounds in the metabolic network of the one-carbon 
metabolism (45) in different populations, and to further explore these relationships 
when people are treated with high doses of synthetic B vitamins. The possible cancer 
promoting effects of folic acid and/or vitamin B12 should be examined by in vitro 
and animal experiments. 
Furthermore, it will be necessary to perform more large-scale epidemiological 
research, especially concerning the ongoing folic acid fortification experiments that 
are currently being conducted in populations world wide. 
As for the NORVIT and WENBIT populations, we will repeat analyses on cancer and 
mortality outcomes after 3 and 7 more years of post-trial follow-up. We will also use 
the data to investigate associations and correlations between baseline demographics 
and clinical characteristics, risk factor levels, biomarkers and metabolites, and clinical 
outcomes. 
It is intriguing that lipid-modifying medications associated with on-treatment 
elevations in plasma tHcy (i.e. fibric acid derivatives and possibly niacin) (176) to a 
lesser extent than statins have demonstrated beneficial effects on hard clinical end 
points, despite having demonstrated presumably beneficial effects on HDL 
cholesterol and triglyceride levels.(177) Studies on mechanisms that may underlie 
these observations, and monitoring tHcy levels in future studies on novel lipid-
modifying drugs, are encouraged. 
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Reference 
68. Wolpin BM, Wei EK, Ng K, Meyerhardt JA, Chan JA, Selhub J, et al. Prediagnostic 
plasma folate and the risk of death in patients with colorectal cancer. J Clin Oncol 
2008;26(19):3222-8. 
shall be replaced by 
68. Giovannucci E, Stampfer MJ, Colditz GA, Rimm EB, Trichopoulos D, Rosner BA, et 
al. Folate, methionine, and alcohol intake and risk of colorectal adenoma. J Natl 
Cancer Inst 1993;85(11):875-84. 
 
Reference 
109. B-Vitamin Treatment Trialists' Collaboration. Analysis plan for a collaborative meta-
analysis to assess the effects of B-vitamins on risk of cancer. Oxford: Clinical Trial 
Service Unit, Oxford University; 2008 August 22. 
shall be replaced by 
109. Western Norway B Vitamin Intervention Trial Steering Comittee. WENBIT – 
Western Norway B Vitamin Intervention Trial. Bergen: Haukeland University 
Hospital; 1999. 
 
At page 58, bottom line, (109) in the text should refer to a new reference (175a) 
175a. B-Vitamin Treatment Trialists' Collaboration. Analysis plan for a collaborative meta-
analysis to assess the effects of B-vitamins on risk of cancer. Oxford: Clinical Trial 
Service Unit, Oxford University; 2008 Aug 22. 
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Appendix II WENBIT forms and questionnaires

WENBIT 
Ved spørsmål angående WENBIT kan du kontakte: 
WENBIT sekretariat  WENBIT sekretariat 
Hjerteavdelingen SPU  Hjerteutredningen / Hjertelaget 
Haukeland sykehus  Sentralsykehuset i Rogaland 
Telefon: 55 97 2171/22 09/22 20  Telefon:51 91 09 10 
Telefax: 55 97 51 50  Telefax:51 91 09 01 
E-post: jady@haukeland.no  E-post: 
7 
Pasientinformasjon 
FORSØK MED B-VITAMINER MOT HJERTE- OG KARSYKDOM 
Senere års forskning tyder på at enkelte B-vitaminer kan ha en viktig beskyttende effekt mot 
utvikling og komplikasjoner av hjerte- og karsykdom. Dette har aldri vært testet ut i vitenskapelige 
forsøk som er den eneste sikre måten for å få slik kunnskap.  
Vi forespørr nå deg og alle andre som skal til hjertekateterisering ved Haukeland sykehus eller ved 
Sentralsykehuset i Rogaland om å delta i et slikt forsøk. Hovedhensikten med studien er å teste ut 
om ekstra inntak av B-vitamintabletter gir færre komplikasjoner og mindre plager senere enten du 
må fortsette med medisinsk behandling alene, blir behandlet med blokking (PTCA) eller må 
hjerteopereres. I forsøket vil tre fjerdedeler av deltakerne bli behandlet med B-vitaminene B6, B12 
og folsyre i forskjellige kombinasjoner, mens en fjerdedel av deltakerne vil få placebo (narretablett). 
For at hverken legen eller pasienten skal kunne påvirke resultatene, vil dette gjøres såkalt blindt 
ved loddtrekning, og koden over hvem som får vitaminer blir ikke åpnet før forsøket avsluttes etter 
tre til fire år.  
Før hjertekateteriseringen vil det bli tatt vanlige blodprøver for analyse av standardprøver som 
kolesterol etc. Spesielt for studien er at det i tillegg vil bli tatt blodprøve som skal fryses ned for 
senere analyser av andre risikofaktorer for hjerte- og karsykdom. Dette gjelder blant annet gener 
som styrer B-vitaminstoffskiftet og stoffer som gjenspeiler inntaket av B-vitaminene. Et av disse 
stoffene er homocystein som er en nyoppdaget og sannsynligvis viktig risikofaktor.  
Du vil få utlevert studiemedisinen samtidig med at du blir informert om resultatet av 
hjertekateteriseringen. Om du videre skal behandles med medisiner, blokking eller operasjon, vil 
avgjøres uavhengig av studien. Studiemedisinen skal du ta en gang daglig. Alle som vil delta i 
forsøket får tilbud om ekstra kontroll og oppfølging etter en måned. Det vil da bli tatt nye 
blodprøver. Deretter vil det være årlige kontroller inntil forsøket avsluttes etter 3-4 år. 
Noen pasienter som blir behandlet med blokking vil få tilbud om en ekstra kontroll et halvt år etter 
blokkingen. Vi ønsker da å utføre ny hjertekateterisering for å undersøke om B-vitaminene 
forebygger tilbakefall. Slike tilbakefall opptrer hos opptil en tredel av de som blir blokket. Dersom 
du ikke blir direkte forespurt om å delta i denne ekstraundersøkelsen, er dette ikke aktuelt for deg. 
Det har ikke vært vist at de vitaminer og i de doser og kombinasjoner som her skal benyttes kan gi 
farlige bivirkninger. Selv om slike bivirkninger derfor er lite sannsynlige, kan de ikke helt utelukkes. 
Opplysninger om alle sykdommer som rammer deltakerne vil derfor bli innhentet fra sykehusene 
og det kan bli aktuelt å hente inn data fra kreftregisteret og dødsårsaksregisteret i Statistisk 
sentralbyrå. Vi ønsker også at du selv fyller ut et ekstra spørreskjema ved kateteriseringen og ved 
kontrollene. 
Produsenten av studiemedisinen har for øvrig egen forsikringsordning for deltagerne. 
Deltagelse i studien er frivillig og du har rett til å nekte å bli med. Du kan også når som helst trekke 
deg fra studien senere uten begrunnelse, men vi anbefaler at du først samrår deg med din lege. 
Alle som har tilgang til persondata er underlagt taushetsplikt. Personnummer brukes kun til å kople 
opplysninger og all annen bruk av data vil foregå uten navn og personnummer. Vi gjør imidlertid 
oppmerksom på at kontrollmyndigheter vil kunne ha behov for å sjekke at opplysninger gitt i 
studien stemmer med opplysninger i din journal for å kontrollere studiens kvalitet. Alle data vil bli 
behandlet strengt fortrolig. 
Skjemaversjon 
ON
WENBIT 
Ved spørsmål angående WENBIT kan du kontakte: 
WENBIT sekretariat  WENBIT sekretariat 
Hjerteavdelingen SPU  Hjerteutredningen / Hjertelaget 
Haukeland sykehus  Sentralsykehuset i Rogaland 
Telefon: 55 97 2171/22 09/22 20  Telefon:51 91 09 10 
Telefax: 55 97 51 50  Telefax:51 91 09 01 
E-post: jady@haukeland.no  E-post:
7 
WENBIT SAMTYKKEERKLÆRING        
      
Jeg har lest pasientinformasjonen og sier meg villig til å delta i forsøket  
WENBIT – VESTNORSK STUDIE AV B-VITAMINER MOT HJERTE- OG KARSYKDOM.  
Dato  |_____|_____|_____| |_____________________________________|         
dag måned år                                        underskrift av pasient 
Undertegnede lege bevitner at ovennevnte pasient har fått muntlig informasjon om 
WENBIT, at vedkommende har lest pasientinformasjonen og underskrevet 
samtykkeerklæringen. 
|_____________________________________|         
underskrift av lege
For sykehuset:
NN aa vv nn --- oo gg aa dd rrree ss ss ee lll aa pp pp
mee dd ss ttt rrree kk kk oo dd ee ss kk aa lll
lll iiimee ss pp åå hh ee rrr iii nn nn ee nn fffoo rrr
fff ee lll ttt ee ttt
BlodprøvenummerWENBIT-nummer
Ved spørsmål angående WENBIT kan du kontakte: 
WENBIT sekretariat  WENBIT sekretariat 
Hjerteavdelingen SPU  Hjerteutredningen / Hjertelaget 
Haukeland sykehus  Sentralsykehuset i Rogaland 
Telefon: 55 97 2171/22 09/22 20  Telefon:51 91 09 10 
Telefax: 55 97 51 50  Telefax:51 91 09 01 
E-post: jady@haukeland.no  E-post:
WENBIT undersøkelser og kontroller 
Vestnorsk studie av B-vitaminer mot 
hjerte- og karsykdom  
Helseregion Vest 
Sentralsykehuset i Rogaland, Stavanger 
Haukeland Sykehus, Bergen 
Hovedprosjekt……..  PTCA subprosjekt…
Aortastenoseprosjekt.  Annet subprosjekt…
Tidspunkt Dato Kl Sted Prosedyrer Skjema 
Dag 00  Blodprøve 
Andre undersøkelser 
Pasientskjema 
KF samtykkeerklæring 
Dag 0  Hjertekateterisering WENBITsamtykkeerklæring 
WENBIT livsstil  
Dag 1    Start med studiemedisin HAD og Mestring 
Kostskjema 
1 måned  Blodprøve 
Samtale 
WENBIT pasientskjema 
6 måneder Gjelder kun deltakere i   
PTCA-studie: Hjertekat. 
PTCA kontroll 
1 år Blodprøve Samtale EKG 
Blodtrykk Høyde Vekt 
WENBIT pasientskjema 
WENBIT livsstil 
2 år Samtale EKG 
Blodtrykk Høyde Vekt 
WENBIT pasientskjema 
WENBIT livsstil 
3 år Samtale EKG 
Blodtrykk Høyde Vekt 
WENBIT pasientskjema 
WENBIT livsstil 
4 år Samtale EKG 
Blodtrykk Høyde Vekt 
WENBIT pasientskjema 
WENBIT livsstil 
5 år Samtale EKG 
Blodtrykk Høyde Vekt 
WENBIT pasientskjema 
WENBIT livsstil 
Bruk av studiemedisin 
1) Én tablett daglig inntil studien avsluttes. Tabletten taes om morgenen, evt sammen med andre medisiner. 
2) De første 14 dagene taes i tillegg én tablett daglig fra liten tablettboks som inneholder totalt 14 tabletter. 
Dersom du glemmer å ta studiemedisinen én eller flere dager, kan du ta uteglemt mengde når du husker det. 
Du får tilsendt ny studiemedisin i posten hvert halvår. Bortsett fra tilleggsboksen for de første 14 dagene, 
inneholder hver boks 200 tabletter. Dette tilsvarer mer enn et halvt års forbruk. Når du mottar ny boks, skal 
du starte å bruke fra denne selv om du altså har tabletter til gode fra den gamle. Den gamle boksen må du 
imidlertid oppbevare, og ved de årlige kontrollene vil du få skriftlig informasjon om å ta med tablettboksen for 
innlevering. 
Annen informasjon 
Du må ikke bruke tilskudd av B-vitaminer eller multivitaminer. Dersom du eller legen din bestemmer at du 
skal starte med slikt tilskudd, må du kontakte oss da dette medfører at du trolig bør slutte i studien. Dersom 
du vurderer å slutte av andre årsaker, eller har spørsmål eller informasjon som gjelder WENBIT, kan du også 
kontakte prosjektsykepleier som vist nedenfor. 
Utgifter til reise dekkes av trygden med vanlig egenandel. Ved evt innleggelser på sykehus må du huske å ta 
med studiemedisinen, fortsette å bruke denne under oppholdet og informere oss om innleggelsen.  
For sykehuset:
NN aa vv nn --- oo gg aa dd rrree ss ss ee lll aa pp pp
mee dd ss ttt rrree kk kk oo dd ee ss kk aa lll
lll iiimee ss pp åå hh ee rrr iii nn nn ee nn fffoo rrr
fff ee lll ttt ee ttt
BlodprøvenummerWENBIT-nummer
3PASIENTSKJEMA
ved hjertekateteriseing  
Helseregion III
Sentralsykehuset i Rogaland, Stavanger 
Haukeland Sykehus, Bergen 
  dag mnd år
Navn/dato …………………………...
 underskrift
Les nøye:  For å få en god vurdering av din hjertesykdom, ber vi deg svare på dette skjemaet og ta det med 
til undersøkelsen. Skjemaet må fylles ut nøyaktig da det benyttes til journalskriving og 
kvalitetssikring. Er du usikker, notérer du i margen. Ved årstall noteres de to siste sifrene.  
Familiebelastning
Har noen i nærmeste familie hatt angina/hjertekrampe/hjerteinfarkt før 70 års alder?  Nei.….   Ja……….. 
Far ………….  Fars søsken..  Fars foreldre..  Egne søsken.   Egne barn…………………. 
Mor………….   Mors søsken..  Mors foreldre.  Søskenbarn...  Vet ikke…………………….
Alder til den med Alder til yngste som Er det tilfeller av plutselig uventet dødsfall i familien før 
tidligst symptom…… døde av hjertet…… 55 års alder hos menn eller 65 års alder hos kvinner?
 alder i år     alder i år Nei…..  Ja………….. 
Røyking 
Aldri røkt……  Evt start Ev sluttet Vis du sluttet siste året, Røkt i total 
Røker fortsatt  ved alder ved alder.. hvor mange mnd siden antall år….. 
alder i år  alder i år  antall mnd  antall år
Hvis du har røkt, hvor mange sigaretter har du røykt pr. dag i snitt? 0-10..  11-20..  Mer enn 20… 
Hvis du fortsatt røker, hvor mange sigaretter røyker du nå pr. dag? 0-10…  11-20..  Mer enn 20… 
Alkohol
Moderat inntak av alkohol kan muligens beskytte mot utvikling av hjertekarsykdom. Dersom 1 enhet alkohol = 1 liten 
flaske pils = 1 glass vin = 1 drink (brennevin), hvor mange enheter drikker du i gjennomsnitt pr uke? 1 fl vin = 6 enheter. 
Intet forbruk… Mindre enn 1. 1-3…. 4-6….   7-12.. Mer enn 12 enheter pr dag. 
Kaffe og te
 0 Ca 1 2-4 Minst 5 Evt hva slags kaffe drikker du oftest? 
Hvor mange kopper kaffe drikker du per dag?  Filter...  Kokekaffe…. 
Hvor mange kopper te drikker du per dag?  Pulver Koffeinfri……
Fysisk aktivitet
Hvor ofte mosjonerer du Aldri  Ca 1 2-3 Minst 4 Evt hva slags   Går tur Jogger Sykler Svømmer Annet 
i gjennomsnitt per uke?……  mosjon er dette?… 
Kolesterol
Høyeste verdi målt (før Hvilket År med kolesterol-  Evt år m full 
evt medikam behandling)   , år målt… senkende medisin   , kostendring 
Vet ikke…… kolesterolverdi  årstall antall år antall år
Høyt blodtrykk 
Har du eller har du hatt høyt blodtrykk? Har blodtrykket vært behandlet med tabletter?  Hvis ja,
Nei………….  Ja…..  Nei….   Ja……..  hvor lenge.. 
antall år 
Sukkersyke
Har du sukkersyke? Ja, hvor Hvis ja, hva slags behandling får du nå? Vis insulin, har du tidl. hatt tablett-
Nei…………..  lenge…. Kost…  Tabletter   Insulin behandling? Nei….   Ja 
antall år
For sykehuset:
NN aa vv nn --- oo gg aa dd rrree ss ss ee lll aa pp pp
mee dd ss ttt rrree kk kk oo dd ee ss kk aa lll
lll iiimee ss pp åå hh ee rrr iii nn nn ee nn fffoo rrr
fff ee lll ttt ee ttt
BlodprøvenummerWENBIT-nummer
3Hjertekarsykdom 
Har du hatt følgende: Nei Ja  Antall ggr  Årstall Har du hatt følgende: Nei Ja Antall ggr Årstall
     
Hjerteinfarkt.…………… |___| |______|  Smerter i leggene ved gange som 
Ballongblokking av forsvinner når en er i ro (røykebein) |___| |______|
kransåre i hjertet……… |___| |______|  Blodpropp i bena…………………. |___| |______|
Bypass-operasjon.……. |___| |______| Operasjon/blokking årene til bena.. |___| |______|
Hjerneslag/drypp.……… |___| |______| Operasjon på hovedpulsåren……. |___| |______|
Operasjon på halsårene. |___| |______| Blodpropp i lungene………………. |___| |______|
    
Andre sykdommer eller plager
Har du eller har du hatt følgende: Nei Ja Har du eller har du hatt følgende: Nei Ja
   
Hjerteflimmer av og til…………………  Kreftsykdom ……………………………………..… 
Hjerteflimmer kronisk………………….  Sår på magesekk, spiserør eller tolvfingertarm… 
Astma, kronisk astmabronkitt/KOLS…  Plager med sure oppstøt eller brystsvie………… 
Annen lungesykdom…………………..  Kronisk tykktarmsykdom…………………………. 
Høyt stoffskifte…………………………  Annen mage/tarmsykdom……………………….. 
Lavt stoffskifte………………………….  Osteoporose/benskjørhet………………………… 
Leddgikt…………………………………  Annen plage fra muskler/skjelettet (senebet. mm) 
Annen reumatisk sykdom…………….  Søvnproblem………………………….…………… 
Psoriasis…..…………………………….  Depresjon………….……..……………………….. 
Utslett eller annen hudsykdom ………  Angst eller annen psykisk plage………………… 
Nyresykdom …..……………………….  Redusert hukommelse…………………………… 
Annen sykdom/plage eller annen kommentar: …………...……………………………………………………………………. 
Vitaminer, tran og kosttilskudd
Hvor ofte bruker du Aldri Av og til Ofte Daglig Hvilke typer tar du (sett evt kryss i flere bokser) 
Vitamin, tabletter………  Multivitamin………..  B-vitamin………. 
Vitamin, flytende………  C-vitamin…………..  E-vitamin……… 
Tran…………………….  A/D-vitamin………..  Folsyre/folat….. 
Jerntabletter……………  Q-10………………..  Selén………….. 
Annet kosttilskudd…….  Fiskeolje/Omega3..  Hvitløk…………. 
Medikamenter (også insulin, vitaminer, kosttilskudd) som du bruker nå
Navn på Tablett- Antall  Antall ggr  Navn på Tablett- Antall Antall ggr 
tablett styrke tabletter  X  pr dag  tablett styrke tabletter  X  pr dag 
pr gg pr gg 
………………………. ……. ……. ……. ………………………. ……. ……. ……. 
………………………. ……. ……. ……. ………………………. ……. ……. ……. 
………………………. ……. ……. ……. ………………………. ……. ……. ……. 
………………………. ……. ……. ……. ………………………. ……. ……. ……. 
………………………. ……. ……. ……. ………………………. ……. ……. ……. 
Allergi
Er du allergisk mot noen medisintyper?  Nei…..   Ja……  Usikker…. 
Evt hva slags reaksjon?……………………………….. Evt mot hvilke medisiner? ……………..…...………………….. 
navn eller type medikament  
Infeksjon og antibiotika 
Har du hatt infeksjon med feber siste året? Har du brukt antibiotika (f. eks. penicillin) siste året? 
Nei…..  Ja……  Nei…..  Ja.…..  Usikker….    
Hvis ja, antall måneder siden siste infeksjon. Hvis ja, hvor mange antibiotikakurer har du tatt……
 antall  antall 
Bare for legen 
ASA Warfa Dipyri ACE-h AT-II-h Betabl Alfabl Ca-bl. Nitro Statin  Resin Amiodar Digitalis Insulin Metform  Sulfon  An adiab 
LM-Hep GPIIb/IIIa An akoag LoopdiurThiazid Spironol NSAID Prednis Imurel Metotrex Cya Antihist B12-inj Folsyre Thyrox Antidep  Østrogen 
Skjemaversjon 
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WENBIT I RESULTATER VED INKLUSJON
Vestnorsk studie av B-vitaminer mot 
hjerte- og karsykdom 
Sentralsykehuset i Rogaland, Stavanger 
Haukeland Sykehus, Bergen 
Helseregion III 
privat arbeid eller mobil 
Sosial status, utdannelse og kjønn 
Gift/samboer  Ugift………   Skilt/separert…  Enke/enkemann.. Kjønn: Mann  Kvinne.. 
Grunnsskole  Videreg….   Høyskole……..  Universitet………
Indikasjon for utredning 1  
Stabil AP..  Stum iskemi..   UAP ØH  Non-Q inf ØH..  Q-inf ØH….  UAP/Inf-nylig2
Inf. tidligere3  Suspekt CAD. 
AS…….  AI….  MI.  MS…….  Annen klaff….  Medfødt vit.  Endocarditt.. 
H(O)CM  CCM  Alv. arrytmi (VT/VF)  Ao-disseksjon  Preop vurd4  Annet..  
1
 Evt kryss i flere ruter.  ØH defineres som utredning ved ØH sykehusinnleggelse 
2 
< 4 uker, polikl. us.  
3
> 4 uker  
4
Også transplantasjonsutredning
Symptom 
 NYHA-klasse Canadian Cardiovascular Society-klasse
Angina pectoris?   Nei  1  2  3  4  0   1  2  3  4a  4b  4c 
Dyspnoe/utmattelse?  Nei  1  2  3  4   
  
Syncope? Nei..  Ja. Vis ØH, antall dager siden symptomdebut  ,
  antall 
Kardiovaskulær sykehistorie 
Antall tidligere tilfeller av 0 1 2 >2 Antall tidligere tilfeller av 0 1 2 >2 
Hjerteinfarkt  Operasjon på halsårene 
PTCA  Perifer emboli 
CABG  Operesjon/PTA perifere kar 
Sykehusinnl. for angina  Operesjon/PTA aorta 
Sykehusinnl. for hjertesvikt  Lungeemboli 
Hjerneslag  DVT 
TIA    
Tidspunkt for evt Tidspunkt for evt Dersom hjerteinfarkt i løpet av siste året, 
første hjerteinfarkt siste hjerteinfarkt… hvor mange måneder siden…………………. 
  årstall årstall antall 
Klinisk undersøkelse 
Høyde Vekt Midje Hofte Systol BT Diastol BT Hjertefrekvens1 
        
  cm kg cm cm mm Hg   mm Hg BPM 
Stenoselyd over karotis…..  Svekket lyskepuls…  Svekket fotpuls…….   1Må samsvare med EKG 
Spirometri og Rtg toraks  
  
Spirometri  VC   FVC%1   FEV-1/FVC PEF%1 Rtg toraks2 2Taes på alle >60 år
Spirometri verdier: Utført………  Ikke utført…    
, Normalt…….  Patologisk..  
Ikke utført…   liter % %    % 
1
Av forventet verdi
EKG 
Normalt ….   RBBB…  LBBB….  PQ-tid S V1 S V3 R aVL R V5 R V6  
Sinusrytme   A. flimm  An. rytm     
Q-infarkt1…  NVI……  FVI…….     
Hemiblokk..  Iskemi…   ms mm  mm mm   mm   mm 
Hypertrofi…  Usp STT forandringer..  QRS Mean QT SD Min QT Max QT 
1
Q-bredde >0,04 sekund og dybde ≥25% av R-takk.
Sokolow-Lyon voltage = S V1 + R V5. V6/V5 ratio = R V6/R V5
Cornell voltage = R aVL + S V3. Cornell product = Cornell voltage x QRS.  ms ms ms    
,
 ms ms 
For sykehuset:
NN aa vv nn --- oo gg aa dd rrree ss ss ee lll aa pp pp
mee dd ss ttt rrree kk kk oo dd ee ss kk aa lll
lll iiimee ss pp åå hh ee rrr iii nn nn ee nn fffoo rrr
fff ee lll ttt ee ttt
Serienummer
Telefon
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AEKG   
AEKG ikke utført.  Maks Maks Maks δ- 
Normal AEKG….   belastning puls.. SBT..  SBT…
Stum iskemi1    Watt BPM mm Hg mm Hg 
Bare symptom Symptom: Angina  Dyspnoe  Manglende BT-stigning 
Symptom+iskemi Iskemi  lokalisert til veggomrode Fremre  Lateral  Nedre    1
≥ 1 mm ST-depresjon. 
Ekkokardiografi 
 Aorta LAD  LVEDD LVESD Septum  Bakre vegg EF Hjertefrekvens 
  mm   mm   mm    mm   mm   mm  % BPM 
 E-maks  A-maks dV/dt  IVRT Ao V-maks cont Ao V-maks LVOT1 LVOT-diam1
, , , , , 
    m/s m/s  m/s2 ms  m/s  m/s cm 
Ingen inf.skade…   Infarktskade i  Septum      Fremre      Laterale    Nedre   
AI grad:   0    1     2    3     4   1 Kun på pasienter med aortastenose
MI grad:   0    1     2    3     4 Ekkokardiografi ikke utført……….. 
LVM=0,83[(LVEDD+septum+bakre vegg)
3
-LVEDD
3
]+0,6. LVMI=LVM/BSA. RWT=2xBakre vegg/LVEDD. 
Hjertekateterisering 
 Dato utført EF EDT Aortagradient1  Aortaklaff areal2 PWP PVR 
, 
 dag måned årstall %  mm Hg  mm Hg   cm2/ m2 mm Hg dynsek cm
-5 
AI grad:   0    1     2    3     4   1 maks  2 korrigert for kroppsoverflate
MI grad:   0    1     2    3     4 
Normale kar…….  Veggforandringer  1-karsykdom  2-karsykdom   3-karsykdom. 
Normale kar etter tidligere utført PTCA….  Réstenose…
Normale venegraft (SBG) etter tidl. CABG  Stenos. SBG  Åpen LIMA  Stenos. LIMA 
LMS-stenose….  LAD-stenose….  CX-stenose…  Intermed-stenose  RCA-stenose 
Ingen inf.skade..  FVI-hypokinesi..  FVI akinesi…  FVI aneurysme 
  NVI-hypokinesi..  NVI akinesi…  NVI aneurysme 
Videre behandling 
Ingen………….  Medikamentell…   PTCA……..    CABG………..  AVR………. 
Annen invasiv1..   Annen operativ.. 1 Rotablator, TMR 
Evt årsak til at invasiv/operativ behandling ikke skal gjennomføres: 
Normale funn…..  Små funn/sympt.  Lav EF…….  Perifere forandringer i koronararteriene 
Alvorlig hjertesykdom med høy risiko…….  Inoperabel…  Alvorlig, ikke-kardial  sykdom…………
Rekruttérbarhet og randomisering i WENBIT 
Rekruttérbar1…..  Randomisert……  Ekskludert…   Ikke rekruttérbar..  
Evt eksklusjonsgrunn: Tidl. randomisert.   Annen studie.   Uegnet2.   Uvillig.   Annen sykd.3  
Evt randomiseringsgruppe: Hovedgr  PTCA gruppe4  Aortastenose….. 
1
Suspekt eller kjent koronarsykdom eller aortastenose 
2 
Mentalt eller fysisk, inklusive misbruk siste 2 år.
3
 Aktiv kreftsykdom, annen alvorlig sykdom 
4
 PTCA-skjema må utfylles
Medikamenter videre
ASA Warfarin  Dipyridamol  ACE-hemmer  AT-II-hemmer  Betabl.   Alfabl.  Calciumbl. Nitroretard   Statin   Resin Amiodarone Digitalis Østrogen 
              
Insulin  Metformin   Sulfonamid  Andre antidiab. NSAIDS Prednison  Imurel Metotrexat    Cya Antihistamin B12-inj.  Folsyre Thyroxin Antidepr
              
LM-Heparin  GP-IIb/IIIa-hemmer Annen antikoag Loop diuretika  Thiazid  Spironolactone
         
Lege
Overlege Overlege vikar Ass.l-D-stilling Ass.l-Utd Annen lege   
        
Skjemaversjon 
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WENBIT pasientskjema
Vestnorsk studie av B-vitaminer mot 
hjerte- og karsykdom 
Helseregion Vest 
Sentralsykehuset i Rogaland, Stavanger 
Haukeland Sykehus, Bergen 
Dato for underskrift 
Navn …………………………..
 underskrift  dag  mnd   år
Kontroll ved: 6 mndr..  1 år.. 2 år.. 3 år. 4 år.. 5 år.. 
Til deg som deltar i WENBIT   For å sikre deg en god kontroll og oppfølging i studien, ønsker vi at du 
svarer på spørreskjemaet og tar det med til undersøkelsen. Skjemaet må fylles ut nøyaktig da det skal leses 
av en maskin. Bruk sort eller blå penn/tusj. Sett kryss i de rutene som passer for deg. Riktig markering av 
kryss i en rute er slik  . Er du uheldig og krysser i feil rute, skraverer du hele ruten . Notér evt i margen. 
Hjertekarsykdom 
Har du siden du sist ble undersøkt av oss i WENBIT-studien hatt (kryss av hvis ja) 
     
Hjertekateterisering…………………………………..  Hjerneslag/drypp………………………………….. 
Ballongblokking………………………………………..  Operasjon på halsårene………………………….. 
Bypass-operasjon……………………………………...  Blodpropp i bena………………………………….. 
Sykehusinnleggelse for hjerteinfarkt……………….  Operasjon eller blokking av årene til bena……… 
Sykehusinnleggelse for hjertesvikt…………………  Operasjon på hovedpulsåren……………………… 
Sykehusinnleggelse for annen hjertesykdom…..  Blodpropp i lungene……………………………….. 
Evt hva slags hjertesykdom…………………………………………………………………………………………. ……………
    
Diverse sykdommer og plager 
Etter at du ble med i WENBIT, har du fått sykdom eller plager som du ikke hadde tidligere, eller er du blitt bedre eller 
værre av plager som du hadde fra før? Du må sette kryss i en av de fem første rutene for hver sykdom eller plage.
Dersom du har vært innlagt på sykehus for noe av dette siden du sist ble undersøkt av oss i WENBIT-studien, må du i 
tillegg sette kryss i det siste feltet. Gi gjerne kommentarer nederst på siden. 
Har vært innlagt
Sykdom eller plage Ingen plage Blitt bedre Uforandret Blitt verre Nyoppstått på sykehus
    
Angina/brystsmerter………………………………… 
Tungpust/åndenød…………………………………… 
Hjerteflimmer………………………………………… 
Astma, kronisk astmabronkitt / KOLS…………….. 
Andre plager fra lungene……………………………. 
Plager med stoffskifte……………………………… 
Leddgikt……………………………………………… 
Annen reumatisk sykdom……………………………. 
Psoriasis……………………….……………………… 
Utslett eller annen hudsykdom…………………….. 
Sår på magesekk, spiserør el tolvfingertarm……… 
Plager med sure oppstøt/brystsvie…………………. 
Kronisk tykktarmssykdom…………………………… 
Annen mage / tarmsykdom………………………… 
Kreftsykdom.………………………………………… 
Nyresykdom ………………………………………… 
Osteoporose / benskjørhet………………………… 
Annen plage fra muskler / skjelettet (senebet. mm) 
Søvnproblemer………………………………………
Depresjon…………………………………………….. 
Angst eller annnen psykisk plage…………………… 
Redusert hukommelse………………………………. 
Infeksjon, uansett lokalisasjon……………………… 
Generelt uvell eller kvalm…………………………… 
Annen sykdom eller plage…………………………… 
Kommentar:……………………………………………………………………………………………………………………………… 
Evt ved hvilket sykehus har du vært innlagt (gjelder også hjertekarsykdom)……………………………………………………. 
For sykehuset:
NN aa vv nn --- oo gg aa dd rrree ss ss ee lll aa pp pp
mee dd ss ttt rrree kk kk oo dd ee ss kk aa lll
lll iiimee ss pp åå hh ee rrr iii nn nn ee nn fffoo rrr
fff ee lll ttt ee ttt
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Røyking 
Aldri røkt..  Sluttet mer enn Sluttet siste året,  Hvis du fortsatt røyker, antall sigaretter per dag i snitt:
Røkr forts  1 år siden  ant mndr siden… 0-10…  11-20  Mer enn 20……….. 
 antall
Alkohol
Moderat inntak av alkohol kan muligens beskytte mot utvikling av hjertekarsykdom. Dersom 1 enhet alkohol = 1 liten 
flaske pils = 1 glass vin = 1 drink (brennevin), hvor mange enheter drikker du i gjennomsnitt pr uke? 1 fl vin = 6 enheter. 
Antall enheter alkohol 0 0- 1 1-3 4-6  7-12 >12 Antall dager per måned 
per uke i snitt………………..  med inntak av alkohol………. . 
antall 
Kaffe og te 
Hvor mange kopper 0 Ca 1 2-4 5-8 >8 Evt hva slags kaffe drikker du oftest (sett evt to kryss)? 
kaffe drikker du per dag…..  Filterkaffe…………..  Kokekaffe…………. 
te drikker du per dag..…….  Pulverkaffe………… Koffeinfri…………… 
Fysisk aktivitet  
Hvor ofte mosjonerer du Aldri  Ca 1 2-3 Minst 4 Evt hva slags   Går tur Jogger Sykler Svømmer Annet
i gjennomsnitt per uke……  mosjon er dette?…… 
Mosjonerer du nå mer eller mindre enn for 1 år siden?……….. Mosjonerer mer……  Mosjonerer mindre… 
Vitaminer, tran og kosttilskudd utenom studiemedisinen 
Hvor ofte bruker du Aldri Av og til Ofte Daglig Hvilke typer tar du (sett evt kryss i flere bokser) 
Vitamin, tabletter…………..  Multivitamin…………  B-vitamin……… 
Vitamin, flytende……………  C-vitamin…………..  E-vitamin…….. 
Tran………………………….  A/D-vitamin…………  Folsyre/folat…. 
Jerntabletter………………..  Q-10…………………  Selén…………. 
Annet kosttilskudd…………  Fiskeolje/Omega3…  Hvitløk…………. 
Infeksjon og antibiotika 
Har du hatt infeksjon med feber siden forrige kontroll? Har du brukt antibiotika (etc penicillin) siden forr. kontroll 
 Nei….  Ja…..  Nei….  Ja…  Usikker…………. 
Hvis ja, antall måneder siden siste infeksjon.. Hvis ja, hvor mange antibiotikakurer………..
  antall  antall 
Medikamenter (også insulin, vitaminer, kosttilskudd) som du bruker nå 
Navn på Tablett Ant tabl Anl ggr Navn på Tablett- Ant tabl Ant ggr  
tablett styrke pr gang pr dag tablett styrke pr gang pr dag  
………………………. …….. ……. ……. ………………………. …….. ……. …….  
………………………. …….. ……. ……. ………………………. …….. ……. …….  
………………………. …….. ……. ……. ………………………. …….. ……. …….  
………………………. …….. ……. ……. ………………………. …….. ……. …….  
………………………. …….. ……. ……. ………………………. …….. ……. …….  
………………………. …….. ……. ……. ………………………. …….. ……. …….  
Evt hvilke medisiner er nye siden siste kontroll i WENBIT: …………………………………………………………… 
Evt hvilke medisiner har du sluttet med siden sist: …………………………………………………………… 
Bare for legen  Ingen endring……... Ingen medisin……..
ASA Warfa Dipyri ACE-h AT-II-h Betabl Alfabl Ca-bl. Nitro Statin  Resin Amiodar Digitalis Insulin Metform  Sulfon  An adiab 
LM-Hep GPIIb/IIIa An akoag LoopdiurThiazid Spironol NSAID Prednis Imurel Metotrex Cya H2-bl Prot-ph B12-inj Thyrox Antidep  Østrogen 
Ur-h     Antihist         Simva Lova Atorva Prava Ceriva Fluva Annet 
+
+ +
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WENBIT kontroll 
Vestnorsk studie av B-vitaminer mot 
hjerte- og karsykdom 
Helseregion Vest 
Sentralsykehuset i Rogaland, Stavanger 
Haukeland Sykehus, Bergen 
    
Mnd-kontroll 1      6     
Årlig kontroll 1     2     3     4     5 
1 Bruk av studiemedikasjon og Status 
Som foreskr  Glemt av & til   Brukt lite/intet Ved årlig kontroll; antall tabletter som 
Brukt for mye ikke er brukt siste året……………………
Vis sluttet, årsak: Trukk samtyk  Advers event  Annen årsak……….     antall 
2 Klinisk undersøkelse (ikke v 1 mnd) 
 Høyde Vekt  Midje Hofte  SBT DBT Hjertefrekv Kvinner:
Hvis nyoppstått  
menopause….   
  cm    kg cm   cm  mm Hg    mm Hg  BPM  alder 
3 Symptom 
Ingen plage Blitt bedre Uforandret Blitt verre Nyoppstått Innlagt sykehus 
    
Angina/brystsmerter…………………………………
Tungpust/åndenød……………………………………   
NYHA-klasse  Canadian Cardiovascular Society Angina-klasse (CCSA)1 
Angina pectoris   Nei  1  2  3  4  0  1  2  3    4a   4b   4c 
Dyspnoe/utmattelse  Nei  1  2  3  4   Syncope?    Nei   Ja 
1 0 Ingen angina. 1 Angina kun ved store fys anstreng. 2 Angina ved normale dagligdagse fys anstreng (etc rask trappegang, fysisk anstreng etter måltid, i kulde eller i vind). 
  3 Betydelig angina ved vanlig lettere fysiske anstrengelser (gange flat vei/opp 1 etage i trapp). 4a Angina også i hvile (ustabil), stabilisert på per oral medikasjon     
  4b Angina også i hvile (ustabil), stabilisert på intravenøs medikasjon.   4c Angina også i hvile (ustabil), ikke stabilisert på intravenøs medikasjon 
4 EKG (ikke v 1 mnd)
Normalt EKG Sinusrytme..    Atrieflimmer…..   PM-rytme…………..  An rytme……………    
Nytt RBBB    Nytt LBBB  Nytt hemiblokk   Ny/økt iskemi……..   Ny/økt hypertrofi……
Nytt Q-FVI  Nytt Q-NVI  Nye uspes for..  Red tidligere forandr   Uforandret  EKG…. 
        
5 Hendelser siden forrige kontroll? (Aktuell arbeidssituasjon ikke v 1 mnd)
Nei…  Planl beh v inklusjon utført uten komplik1..   
Ja……  Planl beh v inklusjon utført med komplik 2  Annet endepunkt3….  SAE4…………………
Akt arb.sit: Hj.vær   Fullt arb  Delvis sykmeldt   Fult sm  Uføretr  Pensjn  Arb.led.. 
Sykmeldt pga hjertet siste året? Sykmeldt av an årsak siste året?
Nei…..  Ja……   Antall dager……….. Nei….  Ja……  Antall dager 
antall antall 
1
ikke endepunkt i WENBIT.
 2
Komplikasjon/forlenget sykehusopphold regnes som endepunkt. 
2,3
Skjema WENBIT hendelser utfylles
4
Serious adverse event, skjema WENBIT-SAE utfylles 
6 Blod- og urinprøve 
Dato  og klokkeslett Fastende? Tid siden måltid Fryseprøve? Urinprøve? Morgenurin?1 U-fryseprøv?
Nei... Nei… Nei… Nei…. Nei….   
Ja…. Ja…… Ja…… Ja…..   Ja…..  
 dag mnd år  nærm time timer  1 Første vannlating   
Prøven tatt ved: HS…..    SiR  FiH….   SSSF.  An SH Primærlege………….  
7 Medikamenter videre  Ingen endring……...  Ingen medisin……..  
ASA Warfa Dipyri ACE-h AT-II-h Betabl Alfabl Ca-bl. Nitro Statin  Resin Amiodar Digitalis Insulin Metform  Sulfon  An adiab 
                 
LM-Hep  GPIIb/IIIa An akoag LoopdiurThiazid Spironol NSAID Prednis Imurel Metotrex Cya H2-bl Prot-ph B12-inj Thyrox Antidep  Østrogen 
                 
Ur-h     Antihist         Simva Lova Atorva Prava Ceriva Fluva Annet 
                 
Ny medisin……………………………………………………… Sluttet med ……………………………………………. 
For sykehuset:
NN aa vv nn --- oo gg aa dd rrree ss ss ee lll aa pp pp
mee dd ss ttt rrree kk kk oo dd ee ss kk aa lll
lll iiimee ss pp åå hh ee rrr iii nn nn ee nn fffoo rrr
fff ee lll ttt ee ttt
BlodprøvenummerWENBIT-nummer
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WENBIT hendelser 
Vestnorsk studie av B-vitaminer mot 
hjerte- og karsykdom 
Helseregion Vest 
Sentralsykehuset i Rogaland, Stavanger 
Haukeland Sykehus, Bergen 
Det må fylles ut 1 skjema for hvert endepunkt. 
Ved alvorlige hendelser (SAE)1 må skjemaet WENBIT-SAE også utfylles. 
1
 Alle hendelser som er dødelige, livstruende, medfører hospitalisering eller forlenget hospitalisering for tilstand som ikke var tilstede før studien ble iverksatt, eller som 
medfører vedvarende fysisk funksjonsnedsettelse. 
Utført behandling planlagt ved randomisering
Nei Ja Nei Ja  
PTCA planlagt ved randomisering…………..   Annen beh. planlagt v. randomis.   
CABG planlagt ved randomisering………….     
  
Endepunkt-type 
Nei Ja Nei Ja  
Død…………………………………………..  Ny CABG……………………………………   
Hjerteinfarkt…………………………………….   Hjerneslag eller TIA……………………….   
Innleggelse for ustabil angina………………..   Subarachnoidalblødning…………………. 
Residivangina etter PTCA…………………….   Lungeemboli……………………………….   
Restenose etter PTCA………………………..   DVT………………………………………….   
Ny PTCA pga réstenose……………………….   Perifer karsykdom1…………………………   
Ny PTCA, ny sykdom………………………….   Innl. for annen hjertesykdom…………….   
PTCA etter CABG…………………………….   Annen årsak til innleggelse………………. 
Angina etter CABG……………………………
1
 Tromboemboli, PTA eller operasjon på aorta eller perifere kar  Evt kommentar: …………………………………
Generelt 
Dato for debut hendelse Dato evt sykehusinnleggelse Dato for evt utskrivning 
  dato    mnd   år  dato  mnd    år dato  mnd   år   
Prosedyrerelatert: hendelse 
< 2 minutt…..  < 1 time…  1-6 t…….   6-24 t ≥ 24 timer 
Prosedyrekode 
Død 
Bevitnet……..  Ikke bevitnet død……………  Plutselig/uventet død……..  Kard sjokk/svikt 
Akutt hjerteinfarkt 
Nytt LBBB….  Q-infarkt….  Non-Q…..  Brystsmerter >20 minutt…..  ST-hevning…  
Positive  enzymer?  Nei……….  Ja.………   
Maksimums- 
verdier av enzymer: 
CK CKMB ASAT Troponin T Troponin I 
Ustabil angina 
Nyoppst EKG-for?  Nei……….  Ja………..   
Positive enzymer?  Nei……….  Ja.………   
Maksimumsverdier
enzymer vis forhøyet: 
CK CKMB ASAT Troponin T Troponin I 
For sykehuset:
NN aa vv nn --- oo gg aa dd rrree ss ss ee lll aa pp pp
mee dd ss ttt rrree kk kk oo dd ee ss kk aa lll
lll iiimee ss pp åå hh ee rrr iii nn nn ee nn fffoo rrr
fff ee lll ttt ee ttt
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PTCA / CABG 
 LMS Prox/Øvr LAD  CX   RCA 
POBA………………   Antall nye Antall gamle 
Stent……………….  stenter….. stenter………. 
LIMA……………….. antall antall 
SBG……………….. 
Klaffeop 
 AS AI MI MS Annen    Mek Biol An graft Plastikk 
Klaffefeil:…………..  Protese/op:………………..   
Karsykdom 
Utf angio/ultralyd/dopler  Nei….  Ja…..  Utført oper?  Nei……..  Ja……………
Evt operasjon lokalisasjon: Intracb  Hals..  Ao asc  Ao abd  Perif kar……. 
Cerebrovaskulær hendelse 
Utført CT eller MR?  Nei….  Ja…..  Lammelse   Talevansk  Perm sequele 
SAH…   Intrac blø  Cerebralt infarkt……  Usp slag..  TIA……   RIND………
DVT eller Lungeemboli 
DVT: Utført UL/venografi? Nei….  Ja….. 
L-emboli: CT/scintegrafi?  Nei….  Ja……   Utført ekko?  Nei………  Ja……………
Diagnosenummer 
 Diagnose 1 Diagnose 2   Diagnose 3 Diagnose 4 
  
Prosedyrenummer og lege 
   Prosedyre 1 Prosedyre 2  Prosedyre 3 Prosedyre 4
Skjemaversjon 
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Appendix III WENBIT organization and approvals

WENBIT organization and approvals 
Steering Committee: Ottar Nygård (chair), Per Magne Ueland, Jan Erik Nordrehaug, 
Dennis W. Nilsen, Stein Emil Vollset, Helga Refsum. 
End-Points Committee: Per Lund-Johansen, MD (chair), Section for Cardiology, 
Institute of Medicine, University of Bergen; Leik Woie, MD, Department of 
Cardiology, Stavanger University Hospital; Marta Ebbing MD, Department of Heart 
Disease, Haukeland University Hospital. 
Safety Committee: Rolv T. Lie, PhD (chair), Section for Epidemiology and Medical 
Statistics, Department of Public Health and Primary Health Care, University of 
Bergen; Terje R. Pedersen, MD, Centre for Preventive Medicine, Ullevål University 
Hospital, Oslo, Norway. 
Funding/Support: WENBIT was funded by the Advanced Research Program and 
Research Council of Norway, the Norwegian Foundation for Health and 
Rehabilitation, the Norwegian Heart and Lung Patient Organization, the Norwegian 
Ministry of Health and Care Services, the Western Norway Regional Health 
Authority, the Department of Heart Disease at Haukeland University Hospital, Locus 
for Homocysteine and Related Vitamins at the University of Bergen, Locus for 
Cardiac Research at the University of Bergen, the Foundation to Promote Research 
Into Functional Vitamin B12 Deficiency, and Alpharma Inc. 
Role of the Sponsors: The main sponsors were nonprofit organizations with no 
participating role in the trial. Alpharma Inc provided the study capsules, generated 
the randomization sequence, and concealed the randomization code free of charge 
and rendered a limited grant to finance the initial phase of the trial. However, 
Alpharma Inc had no role in the design or implementation of the trial, had no access 
to study data, and did not participate in data analysis or interpretation or in the 
preparation, review, or approval of the manuscript. 
Approvals: The study protocol was in accordance with the principles of the 
Declaration of Helsinki, and the trial was approved by the Regional Committee for 
Medical and Health Research Ethics, the Norwegian Medicines Agency, and the data 
handling by the Data Inspectorate. WENBIT was registered with clinicaltrials.gov, 
Identifier: NCT00354081.
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SENDT UT ETTER 6 MND.

SENDT UT ETTER 12+18+24+30+36 MND.
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 NORVIT organization and approvals 
Steering Committee: Knut Rasmussen, MD, PhD (chair); Kaare Bønaa, MD, PhD 
(principal investigator); Egil Arnesen, MD; Per Magne Ueland, MD, PhD; Jan Erik 
Nordrehaug, MD, PhD; Inger Njølstad, MD, PhD; Aage Tverdal, PhD. 
End-Points Committee: Inger Njølstad, MD, PhD (chair); Henrik Schirmer, MD, 
PhD; Terje Steigen, MD, PhD; Harald Wang, MD. 
Data and Safety Monitoring Board: Terje R. Pedersen, MD, PhD, Centre for 
Preventive Medicine, Ullevål University Hospital; Dag S. Thelle, MD, PhD, 
Department of Biostatistics, Institute of Basic Medical Science, University of Oslo; 
Aage Tverdal, PhD, Division of Epidemiology, the Norwegian Institute of Public 
Health; Oslo, Norway. 
Funding/Support: NORVIT was funded by the Norwegian Research Council, the 
Council on Health and Rehabilitation, the University of Tromsø, the Norwegian 
Council on Cardiovascular Disease, the Northern Norway Regional Health Authority, 
the Norwegian Red Cross, the Foundation to Promote Research into Functional 
Vitamin B12 Deficiency, and an unrestricted private donation. 
Role of the Sponsors: The main sponsors were nonprofit organizations with no 
participating role in the trial. Alpharma Inc provided the study capsules free of 
charge. However, Alpharma Inc had no role in the design or implementation of the 
trial, had no access to study data, and did not participate in data analysis or 
interpretation or in the preparation, review, or approval of the manuscript. 
Approvals: The study protocol was in accordance with the principles of the 
Declaration of Helsinki and the trial was approved by the Regional Committee for 
Medical and Health Research Ethics and the Norwegian Medicines Agency. 
NORVIT was registered with clinicaltrials.gov, Identifier: NCT00266487. 
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Hjerteavdelingen 
WENBIT sekretariat 
Hjerteavdelingen, Haukeland Universitetssykehus 
Telefon: 55 97 21 71 
Telefax: 55 97 21 50 
E-post: janne.dyngeland@helse-bergen.no
Bergen, 3. september 2007 
Resultater fra WENBIT studien 
Kjære deltaker! 
Først og fremst vil vi få takke deg for at du var med i WENBIT studien. Vi takker også for at du har vært 
tålmodig i forhold til resultatet, som har latt vente på seg.  
I alt 3090 pasienter, de aller fleste med kransåresykdom, deltok i WENBIT. Totalt 969 deltakere ble fulgt 
opp ved Stavanger Universitetssykehus og 2121 ble fulgt opp ved Haukeland Universitetssykehus. 
Studien ble avsluttet litt før planen oktober 2005. En del pasienter møtte til siste studiekontroll utpå 
nyåret 2006. 
Hovedspørsmålet i WENBIT studien var om det å ta B-vitaminer kunne forebygge utvikling av hjerte-
karsykdom og påvirke dødeligheten hos pasienter med kransåresykdom. Pasientene fikk en av fire ulike 
typer studiemedisin (kapsler), som skulle tas en gang daglig. Det var tilfeldig hvilke pasienter som fikk 
hvilken studiemedisin, og verken pasienter eller studiepersonell (sykepleiere og leger) visste hvem som 
fikk hva undervegs. 
1. Pasienter i gruppe 1 fikk folsyre, vitamin B12 og vitamin B6 
2. Pasienter i gruppe 2 fikk folsyre og vitamin B12 
3. Pasienter i gruppe 3 fikk vitamin B6 
4. Pasienter i gruppe 4 fikk placebo, det vil si ”narremedisin” 
Vi har nå åpnet koden for hvem som fikk hvilken studiemedisin og undersøkt om det å ta B-vitamin 
tilskudd var gunstig for deltakerne. 
Du var i gruppe
Blodprøvene viste som forventet at pasientene i gruppe 1 og 2 fikk høyere verdier av folsyre og vitamin 
B12, og lavere verdier av homocystein. Homocystein er et stoff som blant annet markerer risiko for 
hjerte-kar sykdom. 
Vi fant vi ingen holdepunkt for at det å ta de ulike B-vitamin tilskuddene var gunstig eller ugunstig når 
det gjelder sykdomsutviklingen og risiko for død. Slik sett er WENBIT resultatet ”nøytralt”. Selv om 
dette kanskje var litt skuffende, er også et ”nøytralt” vitenskapelig resultat viktig. Vi har nå ingen grunn 
til å anbefale B-vitamin tilskudd for pasienter med kransåresykdom. 
Som du kanskje husker, var det i forbindelse med en annen tilsvarende norsk studie (NORVIT) spørsmål 
om B-vitamin tilskudd kunne være farlig, og kanskje øke risikoen for kreft. Vi har ikke funnet holdepunkt 
for dette i WENBIT. 
Hjerteavdelingen 
Resultatene fra WENBIT studien blir første gang presentert offentlig 4. september 2007 på den 
europeiske hjertekongressen, som i år arrangeres i Wien. Vi vil også publisere resultatet i et anerkjent 
vitenskapelig medisinsk tidskrift, men det kan ta tid før en slik artikkel foreligger. 
Mer informasjon om WENBIT studien kan du finne på internettsiden til Haukeland Universitetssykehus 
på www.helse-bergen.no
Hvis du lurer på noe vedrørende din deltakelse i studien, kan du ta kontakt med WENBIT sekretariatet, se 
nedenfor.
Nok en gang: Takk for at du har bidratt til medisinsk forskning! 
Med hilsen 
Ottar Nygård, professor / prosjektleder 
WENBIT sekretariat 
Hjerteavdelingen, Haukeland Universitetssykehus 
Telefon: 55 97 21 71 
Telefax: 55 97 21 50 
E-post: janne.dyngeland@helse-bergen.no
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